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Prolonged sitting (PS) is associated with venous pooling (VP) and increased central 
arterial stiffness (AS). Brachial femoral pulse wave velocity (bfPWV) and hemodynamics were 
examined in 11 participants before and after 120 minutes of sitting (SIT, n = 5, 23.6 [5.3] y, 40% 
F, 23.1 [3.2] kg/m2) or lying (LAY, (n = 6, 26.5 [7.6] y, 66.7% F, 22.5 [2.3]). Participants were 
recruited to either the SIT or LAY group and had two conditions applied in separate visits: i) 
CUFF, where occlusive cuffs were applied legs to induce greater VP and ii) NON CUFF, a 
control condition. In the SIT trial, bfPWV showed nonsignificant (p = 0.28) increases in both 
CUFF and NON CUFF conditions with greater increases in CUFF (5.93 ± 0.7 to 6.33± 0.6 m/s) 
than in NON CUFF (6.4 3±2.6 to 6.9±2.6). The data indicate that VP manipulation is associated 














I am indebted to my advisor, Dr. Lee Stoner, for providing me with this opportunity to 
return to the University of North Carolina at Chapel Hill to continue my education, challenge my 
intellect and further understand the complexities of the human body. This program, with his 
guidance, expanded my horizons; with his help, I have grown as a researcher and a teammate.  
Thank you to my colleague and friend, Alex Pomeroy, for your endless positivity and 
hard work. It has been a privilege to work with you these last two years. To the UNC 
Cardiometabolic Lab and my cohort: you all are an incredible group of scientists. I appreciate 
each one of you. 
To my husband Kent Torell: I am continuously amazed at how we have found ourselves 
at another grand stage of life together. His support was indispensable as I transitioned from 
employee to student as he did the opposite, and when I was called back to hospital duty by the 
pandemic, he remained steadfast in his care for my physical and mental wellness.  
Words fail to express the full extent of my love and appreciation to my parents and 
family for their unwavering encouragement: to Mom, who always looks for a reason to celebrate 
and find joy; to Papa J, who, since I was a child, emphasized “be proud of your work!” Thank 





TABLE OF CONTENTS 
 
LIST OF TABLES ......................................................................................................................... ix 
LIST OF SUPPLEMENTARY TABLES ....................................................................................... x 
LIST OF FIGURES ....................................................................................................................... xi 
LIST OF ABBREVIATIONS ....................................................................................................... xii 
DEFINITION OF TERMS .......................................................................................................... xiv 
CHAPTER I: INTRODUCTION .................................................................................................... 1 
ASSUMPTIONS, DELIMITATIONS & LIMITATIONS ......................................................... 3 
Assumptions ............................................................................................................................ 3 
Delimitations ........................................................................................................................... 3 
CHAPTER II - REVIEW OF LITERATURE ................................................................................ 5 
INTRODUCTION TO TOPIC .................................................................................................... 5 
DEFINITIONS ............................................................................................................................ 5 
Sedentary Behavior .................................................................................................................. 5 
CHRONIC SEDENTARY BEHAVIOR IS ASSOCIATED WITH CVD ................................. 6 
ACUTE PROLONGED SITTING IMPAIRS CARDIOVASCULAR FUNCTION ................. 7 
Sitting Increases Venous Pooling ............................................................................................ 8 
 
vi 
Venous Pooling Alters Systemic Hemodynamics ................................................................... 9 
Prolonged Sitting Promotes Endothelial Dysfunction ............................................................. 9 
Gaps in Knowledge ............................................................................................................... 11 
WHY IS THIS STUDY NEEDED? .......................................................................................... 12 
METHODOLOGICAL AND RIGOR CONSIDERATIONS................................................... 13 
Study Design Considerations................................................................................................. 13 
Measurement Considerations ................................................................................................ 14 
Internal Validity ..................................................................................................................... 16 
Population/ Sampling ............................................................................................................ 17 
Biological Factors .................................................................................................................. 18 
External Validity / Generalizability ....................................................................................... 18 
STATISTICAL CONSIDERATIONS .................................................................................. 19 
SUMMARY .............................................................................................................................. 20 
Why is this study needed? ..................................................................................................... 20 
What is known ....................................................................................................................... 20 
What is not known ................................................................................................................. 20 
Critical Need .......................................................................................................................... 21 
CHAPTER III: METHODOLOGY .............................................................................................. 22 
PARTICIPANTS ....................................................................................................................... 22 
EXPERIMENTAL DESIGN..................................................................................................... 22 
 
vii 
PREASSESSMENT GUIDELINES AND FAMILIARIZATION ....................................... 23 
EXPERIMENTAL VISITS ................................................................................................... 24 
EXPERIMENTAL MEASURES .............................................................................................. 27 
Independent Variable: Venous Pooling ................................................................................. 28 
Dependent Variable: Central Arterial Stiffness ..................................................................... 29 
RANDOMIZATION ................................................................................................................. 30 
SAMPLE SIZE .......................................................................................................................... 30 
QUALITY CONTROL ............................................................................................................. 30 
DATA MANAGEMENT AND STATISTICAL ANALYSIS ................................................. 31 
CHAPTER IV: RESULTS ............................................................................................................ 32 
PARTICIPANTS ....................................................................................................................... 32 
HARMS ..................................................................................................................................... 33 
SIT TRIAL ................................................................................................................................ 34 
Venous Pooling...................................................................................................................... 34 
Arterial Stiffness .................................................................................................................... 35 
Secondary Outcomes ............................................................................................................. 36 
LAY TRIAL .............................................................................................................................. 39 
Venous Pooling (LAY) .......................................................................................................... 39 
Arterial Stiffness (LAY) ........................................................................................................ 40 
Comparisons to SIT Trial ...................................................................................................... 41 
 
viii 
CHAPTER V: DISCUSSION ....................................................................................................... 43 
LIMITATIONS AND STRENGTHS ....................................................................................... 43 
COMPARISON TO LITERATURE ......................................................................................... 44 
IMPLICATIONS ....................................................................................................................... 47 
CONCLUSIONS ....................................................................................................................... 48 
APPENDIX A: CONSENT .......................................................................................................... 49 
APPENDIX B. SUBJECT PRE-ASSESSMENT INSTRUCTIONS ........................................... 58 
APPENDIX C. SUPPLEMENTAL DATA .................................................................................. 59 





LIST OF TABLES 
 
 
Table 1: A review of the literature on sitting studies on arterial stiffness, 
venous pooling, and endothelial dysfunction.....................................................................12 
 
Table 2:  Procedures to control internal validity in participant recruitment and 
testing. ................................................................................................................................17 
 
Table 3: Eligibility and exclusion criteria. ....................................................................................18 
 
Table 4: Arterial stiffness parameters and central hemodynamics in the SIT 
trial . ...................................................................................................................................37 
 
Table 5: Afterload, inotropy and sympathetic nervous system parameters in 
the SIT trial, before and after conditions applied.. ............................................................39 
 






LIST OF SUPPLEMENTARY TABLES 
 
 
Table S1: Brachial-femoral pulse wave velocities reported as mean 
(standard deviation) before and after 120 minutes of lying (LAY) or 
sitting (SIT). (n = 11) .........................................................................................................60 
 
Table S2: Calf circumferences reported as mean (standard deviation) before 
and after 120 minutes of lying (LAY) or sitting (SIT).  (n = 11) ......................................61 
 
Table S3: NIRS measures reported as mean (standard deviation) before and 
after 120 minutes of sitting  (n = 5) ...................................................................................62 
 
Table S4: NIRS measures reported as mean (standard deviation) before and 
after 120 minutes of lying.  (n = 6) ....................................................................................63 
 
Table S5: Preload and cardiac output parameters in the LAY trial presented 
as mean (standard deviation) (n = 6)..................................................................................64 
 
Table S6: Afterload, inotropy and sympathetic nervous system parameters 
in the LAY trial, presented as mean (standard deviation) (n = 6)......................................65 
 
Table S7: Participant Characteristics for the SIT study (n = 5) and LAY 




LIST OF FIGURES 
 
Figure 1: Proposed conceptual model theorizing how prolonged sitting 
leads to venous pooling, hemodynamic changes, and ultimately 
increases in arterial stiffness.. ..............................................................................................7 
 
Figure 2: Crossover design with randomization of first visit condition. LAY 
and SIT trials were conducted separately. .........................................................................23 
 
Figure 3: Design for the A) SIT study and B) LAY study.. ..........................................................26 
 
Figure 4: CONSORT diagram for recruitment and testing of the LAY and 
SIT trials. bfPWV, brachial femoral pulse wave velocity; NIRS, 
near-infrared spectroscopy. ................................................................................................33 
 
Figure 5: Mean SIT trial calf circumference (5A) and HHb (5B) over time 
and by condition with SE bars.. .........................................................................................35 
 
Figure 6: Changes in bfPWV (m/s) over 120 minutes in the SIT group. 
Slope for condition and time shown in upper right corner.. ..............................................36 
 
Figure 7: LAY trial calf circumference (7A) and HHb (7B) over time and 
by condition.. .....................................................................................................................40 
 





LIST OF ABBREVIATIONS 
 
AS Arterial stiffness 
AIx Augmentation index 
bfPWV Brachial-femoral pulse wave velocity 
cfPWV Carotid-femoral pulse wave velocity 
CML Cardiometabolic Laboratory  
CO Cardiac output 
CONSORT Consolidated Standards of Reporting Trials 
cSBP Central systolic blood pressure 
CVD Cardiovascular disease 
D Arterial pathlength 
ET-1 Endothelin -1 
faPWV Femoral-ankle pulse wave velocity 
GSR Galvanic skin sensitivity 
HR Heart rate 
MAP Mean Arterial Pressure 
METs Metabolic equivalents 
NIBP Non-invasive blood pressure 
NIRS Near-infrared spectroscopy 
PS Prolonged sitting 
PWA Pulse wave analysis 
PWV Pulse wave velocity 
SB Sedentary behavior 
 
xiii 
SMII Smith-Madigan Inotropy Index 
SVR Systemic vascular resistance 
SV Stroke volume 
SVV Stroke volume variation 
TT Transit time 





DEFINITION OF TERMS 
 
Afterload The pressure the left ventricle must overcome to eject stroke volume per 
beat 
Arterial Stiffness The rigidity or compliance of a blood vessel, based on its cellular and 
structural components. 




The process by which the muscle contractions of the gastrocnemius aid 
venous return from lower limbs by generating ambulatory pressure 
Inotropy The contractility of the heart, i.e., the force of each contraction 
Preload The initial stretching of the cardiac myocytes prior to contraction. 
Pulse wave 
velocity 
Distance traveled by pulse wave divided by the time it takes for the pulse 
wave to travel that distance (meters/second). A metric of arterial stiffness. 
Pulse Wave 
Analysis 
An algorithm that can derive central hemodynamic metrics, including cSBP 
and AIx, from a pulse wave measurement. 
Prolonged sitting An acute bout of sitting lasting longer than 30 minutes 
Sedentary 
Behavior 
Any waking behavior characterized by an energy expenditure ≤1.5 
metabolic equivalents (METs), while in a sitting, reclining, or lying posture. 
Stroke Volume The milliliters of blood ejected by the left ventricle during systole 





CHAPTER I: INTRODUCTION 
 
Epidemiological evidence has established that prolonged sitting (PS) increases the risk of 
cardiovascular disease (CVD) risk and all-cause mortality.1–3 This is a public health concern 
because CVD risk is currently the leading cause of death in the United States, while the 
prevalence of sedentary behaviors has grown.4 American adults spend most of their waking 
hours sitting for extended time periods.5 Acute bouts of sitting have been shown to increase 
arterial stiffness, an independent risk factor for CVD and a contributing factor for 
atherosclerosis.6,7 CVD hazards from PS are not entirely attenuated by achieving recommended 
physical activity levels, indicating that sitting is a unique risk factor.2,8 Furthermore, it is 
estimated that half of deaths from atherosclerotic cardiovascular disease are attributed to lifestyle 
factors.4  Sedentary behavior is one such factor that includes PS, which alters systemic blood 
circulation and increases venous pooling (VP) in the lower extremities.9,10 Decreased venous 
return results in the activation of many physiological pathways to compensate for reduced blood 
flow to the heart; among these processes are changes that lead to stiffer arteries.11 However, 
while it is well-known that PS increases CVD risk, the mechanisms that cause arterial stiffening 
after acute bouts of sitting are largely unknown, including whether VP directly contributes to this 
deleterious process. Chapter II will introduce a proposed model that seeks to explain the 
physiological cascade that suggests increased VP leads to arterial stiffness. 
The long-term goal of this research is to determine the acute effects of VP on 
cardiovascular health in the context of PS, with the specific objective of identifying VP as 
contributing factor in the physiology increasing arterial stiffness. No study to our knowledge has 
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examined the vascular changes after attenuating the amount of VP in the lower limbs during 
acute bouts of sitting. This study better illustrates the relationship between VP and acute changes 
in vascular health:  identifying the strength of their association will further explain the 
mechanism between sitting exposures and CVD. Further, there is a need for guidelines as well as 
effective strategies in interrupting bouts of sedentary behavior. While many more studies will be 
needed to establish optimal prescriptions to prevent adverse outcomes from PS, examining ways 
to diminish VP could offer more efficacy in sitting interruption strategies. To mediate the 
hazards associated with PS, VP must first be identified as influential to the progression of arterial 
stiffness. To verify this influence is to better understand the process that leads to impaired vessel 
function and hemodynamic disruptions. This knowledge can lead to better health 
recommendations including evidence-based sitting interruption strategies and more informed 
public health guidelines on mediating hazards from PS. 
The primary hypothesis is that increased VP results in subsequent increases in arterial 
stiffness, an indicator of cardiovascular health and vessel compliance. To test the hypothesis, this 
study examined VP between participants: one bout of sitting with occlusive cuffs to increase VP 
was compared to another bout of PS without augmenting VP. Arterial stiffness and VP were 
assessed and compared among participants between the two conditions. Furthermore, to deduce 
whether body position plays a role in physiological changes, a second group of participants was 
recruited to examine one bout of lying with occlusive cuffs to induce VP, compared to a bout of 





Aim 1: Determine acute effect of venous pooling manipulation on central arterial stiffness. 
Young, healthy participants completed two conditions: a control session of prolonged sitting 
(120 minutes), and prolonged sitting with bilateral leg tourniquets inflated.  
A second group of participants will complete two conditions: one control session of 
uninterrupted supination (120 minutes), and one uninterrupted supination with bilateral leg 
tourniquets inflated. 
The primary outcome is arterial stiffness (AS), and the secondary outcome is venous pooling 
(VP). 
Research hypotheses: 
1. During PS, VP will increase, and AS will increase. 
2. During conditions with bilateral leg tourniquets, VP will increase more than it measured in the 
control condition, and AS will increase more than it measured in the control condition. 
 
ASSUMPTIONS, DELIMITATIONS & LIMITATIONS 
Assumptions 
• Central venous pressure was assumed to be 0 mmHg in pressure and output calculations. 
• Participants truthfully answered their screening medical questionnaire. 
•  Participants followed pre-assessment guidelines. 
•  Placement of devices (VICORDER®, NIRS, USCOM Doppler) were similar between 
two visits. 
Delimitations 
1. All participants fasted 8 hours prior to testing. 
2. Two hours of sitting has been shown in the literature to cause acute vascular alterations. 
3. Researchers encouraged no movement during the sitting conditions. 
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4. Passive movement from supine rest to sitting position negligibly engaged lower limb 
muscles. 
5. Participants were scheduled only in the morning. 





CHAPTER II - REVIEW OF LITERATURE 
 
INTRODUCTION TO TOPIC 
Prolonged sitting (PS) is a widespread behavior present in recreational activities, 
occupational settings. and in transportation. American adults spend 50-70% of their waking 
hours sitting.5,12 While meta-analyses have shown a strong link between PS and cardiovascular 
disease (CVD), including coronary artery disease and cerebrovascular accidents3,13, the 
mechanism by which sitting results in this elevated risk is not understood. In order to take action 
on this public health issue, research must elucidate the association between chronic sitting and 
CVD risk, i.e., the acute physiological changes that occur during PS must be identified first. 
The following literature review will support the proposed mechanism, of how PS contributes 
to a series of vascular changes and arterial stiffness. It will also highlight gaps in the literature, 
including those the study seeks to address. 
DEFINITIONS 
Sedentary Behavior 
Sedentary behavior (SB) is defined as any waking behavior characterized by an energy 
expenditure of  1.5 metabolic equivalents (METs) or less while in a sitting, reclining, or lying 
posture.14 SB is distinct from a physical inactivity, meaning that an individual has not met the 
recommended 150 minutes of moderate to vigorous physical activity per week.15 Distinguishing 
sedentary behavior from a lack of physical activity is necessary because the two are mutually-
exclusive risk factors for CVD. Prolonged periods of sedentary behavior remain hazardous even 
if the recommended amount of physical activity is met.2,3,8  Certain trends in both physical 
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activity and sedentary behaviors are concerning. Rates of automobile dependence have risen, 
fewer people use walking as transportation, and physical activity in occupational and domestic 
spaces have decreased.16,17 TV-viewing time, usually a sedentary activity in itself, has also 
risen.16 Further, driving a car, office work and watching TV are the most common contributions 
to daily energy expenditure, aside from sleeping, indicating low levels of activity in the general 
population.18 These patterns suggest poorer CVD outcomes in the future. Identifying sedentarism 
as a distinct risk factor is essential in studies examining its physiology. 
CHRONIC SEDENTARY BEHAVIOR IS ASSOCIATED WITH CVD 
It has been well-established that more time spent in sedentary pursuits is associated with 
CVD.2,13 CVD risks significantly increase when adults sit for more than 6 hours per day, even 
after adjustments for physical activity.3 The average American spends 7.7 hours per day in these 
low-energy behaviors, well above the threshold for elevated risk.5 A recent metanalysis 
determined that those who sit longer than 8 hours/day and engage in minimal physical activity 
had a 59% increase in all-cause mortality risk relative to the individuals who sit less than 4 
hours/day and engage in high levels of physical activity.19 However, even when less dramatic 
differences in energy expenditure are observed between groups, it is evident that sitting for 
extended periods of time poses health risks. CVD is the leading cause of death worldwide, yet it 
is estimated that approximately half of the deaths attributed to atherosclerotic CVD are 
preventable with lifestyle modifications.4 With sedentary behaviors already prevalent and trends 
showing inactivity increasing in occupational and domestic settings, preventative health 





ACUTE PROLONGED SITTING IMPAIRS CARDIOVASCULAR FUNCTION 
Prolonged sitting is known to impair vascular health in acute doses by altering systemic 
hemodynamics and impairing endothelial function in an effort to maintain homeostasis.7,20 The 
first step in the process by VP, where blood collects in the distal lower limbs. The lack of 
skeletal muscle pump, increased hydrostatic pressure, and bending in the limbs contribute to 
increased VP in a seated position, reducing venous return.21,22 Furthermore, this reduction in 
venous return is thought to decrease shear stress, weakening endothelial cell vasodilatory 
responses and its atheroprotective phenotype23–25.  
 
Figure 1: Proposed conceptual model theorizing how prolonged sitting leads to venous pooling, 
hemodynamic changes, and ultimately increases in arterial stiffness. MAP, mean arterial pressure; SVR, 




As shown in Figure 1, these systemic and local vascular alterations both contribute to 
increased arterial stiffness, a measure of vascular health, as well as an independent risk factor for 
poorer cardiovascular outcomes. Therefore, examining the circulatory effects of PS is the first 
step in investigating the process by which sitting results in diminished vascular health.  
 
Sitting Increases Venous Pooling 
PS results in decreases in blood flow and increases in blood pooling in the lower 
legs.9,24,26,27 The first complication from venous pooling is the decrease in venous return. Venous 
return, the venous blood that arrives from the periphery to the right side of the heart, is essential 
for the maintenance of cardiac output. CO is equal to its inflow and is the cornerstone of 
hemodynamic equilibrium.28–30  
Several processes lead to lower limb pooling.31 Immobility from sitting does not engage 
the lower limb muscles, resulting in blood pooling and consequent hemodynamic adaptations. 
During walking, skeletal muscles squeeze blood from the legs back to the inferior vena cava and 
heart venous return is maintained.32 Conversely, in the absence of these muscular contractions, 
blood pools in the lower limbs.27 Approximately 90% of venous return in the lower extremities is 
through foot, thigh, and calf muscle pumps, making it evident that their disuse in sitting is a 
considerable contributor to VP.33  The subsequent reduction in venous return from PS has major 
negative implications on cardiac output. 
In addition, blood pooling is exaggerated by rising hydrostatic pressure in the lower limbs 
during sitting. Hydrostatic pressure is defined as the pressure at any point of a fluid subjected to 
gravity, in this case the intravascular fluid, which can be dramatically increased by gravity 
depending on bodily position.32 The lower limbs experience increased gravitational fluid shifts 
during head-up tilt positions, creating greater blood pressure in the lower limbs when compared 
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to supine positions.32,34 Changes in bodily position stimulates the arterial baroreflex, where the 
decrease in blood pressure from hydrostatic fluid shift stimulates a sympathetic response.  
Venous Pooling Alters Systemic Hemodynamics 
On both a microvascular and systemic level, venous stasis produces deleterious changes. 
Venous return is dampened due to VP after PS, thus, right sided filling pressure and preload 
decrease. Preload, one of the three primary mechanisms that regulate stroke volume, is necessary 
to maintain end-diastolic volume, the amount of blood in the left ventricle before ejection29. 
Therefore, diminished blood ejected from the heart results in decreases in CO and, subsequently, 
MAP. This unloads the carotid and aortic baroreceptors, which respond by enacting the 
sympathetic nervous system.35 Breaking up sedentary behaviors with walking and exercise 
lowers plasma norepinephrine, a surrogate measure for sympathetic activation, supporting the 
process in the proposed model that venous pooling contributes to upregulation of the sympathetic 
nervous system.36  Upregulating sympathetic activity increases systemic vascular resistance 
(SVR), thereby decreasing the compliance of peripheral vessels, increasing stiffness and 
augmenting arterial wave reflection. These increases augment left ventricular afterload, further 
compromising CO37. The results of this cascade, including higher values of PWV and systolic 
hypertension, are strongly associated with adverse cardiovascular events.38 Without adequate 
venous return, right-sided filling pressure is reduced, subsequently decreasing preload. 
Consequently, the cardiovascular system must adapt to maintain cardiac output, including 
increasing stiffness. 
Prolonged Sitting Promotes Endothelial Dysfunction 
The decrease in venous return due to pooling affects arteries on a cellular level in both 
the large conduit vessels as well as peripheral vessels, particularly those in the legs. Several 
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processes occur that impact the function of endothelial cells in the aorta and in the peripheral 
arteries. First, decreases in venous return due to pooling decreases aortic shear stress, the drag 
force acting on the endothelium from blood flow. Second, the biomechanics of sitting, 
specifically the bending at the hip and knee, reduces popliteal blood flow, lowering shear forces 
and inducing endothelial dysfunction in peripheral vessels.20,22,39Popliteal blood flow reduction 
begins within as little as 10 minutes of sitting, suggesting that the changes in shear stress may be 
attenuated quickly as well.9 
Endothelial cells lining the inner lumen of the aorta are stimulated by shear stress to 
synthesize nitric oxide and other vasodilators. Laminar shear stress mediates nitric oxide 
synthase, an enzyme that creates nitric oxide from l-arginine. Lower shear forces on these cells 
inhibits proliferation of endothelial nitric oxide synthase in addition to deterring downregulation 
of endothelin-1 (ET-1), a potent vasoconstrictor. PS invokes low and oscillating (turbulent) shear 
forces which are associated with atherosclerotic lesion formations; in contrast, higher, laminar 
shear stresses are associated with atheroprotective gene expression.25,40 Several studies suggest 
that the endothelial dysfunction may also play a role in the inflammatory processes that occur 
prior to plaque formation.25,41,42 The detrimental effect of sitting on shear stress and the resulting 
endothelial dysfunction suggests that this pathway could have implications for CVD risk.  
 Viscoelastic properties of large arteries are essential in storing and delivering stroke 
volume to the body.37 The inverse of arterial compliance, the ability of the vessel to dilate in 
response to volume changes, is arterial stiffness (AS). However, to measure AS is not only a 
method of assessing vascular compliance, but also a means of measuring vascular function. 
Arteries rely on endothelial cell production of nitric oxide and other mediators in its ability to 
dilate 20,43 Endothelial cells also have key functions in immune response.44 Studies show that AS 
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increases and endothelial function diminishes after acute bouts of sitting.6,7 The arteries’ 
incapability to function properly could be the link between PS and CVD risk because AS is 
another known risk factor associated with cardiovascular pathologies. Thus, understanding how 
PS leads to AS may paint a broader picture as to what forces drive CVD risk.  
Gaps in Knowledge 
Table 1 is selection of studies that examine PS to distinguish it among sedentary 
behaviors. It is evident that AS has been studied in the context of endothelial dysfunction and 
central hemodynamics, but VP remains a secondary outcome measure, if measured at all. To our 
knowledge, no study has examined sitting with induced increases in VP to compare its 
subsequent effects on arterial stiffness and hemodynamics.  
Furthermore, while some studies compared endothelial function between supine groups 
and seated groups,22 no study examined a supine group to examine if VP has a synergistic effect 






Study details Relevant 
measures 




5 hours (total) sitting: increases 
in diastolic and MAP, calf 
pooling increased 
 Did not measure 
VP by calves; did 
not measure PWV 
1. Hemodynamic 
changes 




6 hours sitting: mean 
shear rate significantly decreased. 
Popliteal blood flow decreased. 
Increase in calf circumference. 
Mean increase calf 
circumference 








3 hours sitting: increase in 
aPWV from pre-sitting to post 
sitting; increase in calf 
circumference 
Increase in aPWV 
from 5.7 m/s to 6.1 
m/s: calf 
circumference 
from 40 cm to 42 
cm 
1. Arterial stiffening 




3 hours sitting: increases in calf 
circumference, reductions in FMD 
and 
of hyperemic blood flow AUC 
Calf circumference 
in men: 37.9 cm to 
38.9 cm; in 








3 hours sitting between 
stationary group and sitting 
group with intermittent calf 
raises: increase in aortic PWV. 
Non-significant difference in total 
hemoglobin between groups.  
cfPWV increased 
by 0.3 m/s; NIRS 
showed THb was 
1.9µM higher in 
control group (non-
significant).  
1. Arterial stiffening 




Two 3-hour 40 min “workdays” 
of continuous sitting vs. 
intermittent sitting/standing 
groups: slight decrease in 
peripheral PWV between groups47 
caPWV was lower 
in sit/stand group 
than sitting group 
(-0.27 m/s) 
1. Arterial stiffening 
Table 1 : A review of the literature on sitting studies on arterial stiffness, venous pooling, and endothelial 
dysfunction. 
 
WHY IS THIS STUDY NEEDED? 
While VP has been shown to increase during bouts of PS, it has not been independently 
studied as a causative factor in altering vascular health. Should VP be identified as a factor in the 
gap between prolonging sitting and impaired vascular health, methods to interrupt this process 
can be developed with the logic of attenuating VP in sedentary populations. Furthermore, current 
guidelines on reducing sedentary behaviors are absent in many public health policies. Those that 
 
13 
do exist are typically vague, e.g., “sit less,” or “break up long periods of sitting as often as 
possible.”48 Identifying specific factors that elevate risk of CVD such as VP provides the 
foundation to research sitting interruptions. Simple, evidence-based recommendations may be 
more effective to communicate to the public. 
METHODOLOGICAL AND RIGOR CONSIDERATIONS 
Study Design Considerations 
Several potential study designs were considered in pursuing the research question. A 
cross-sectional design could be conducted but has limitations in establishing temporality. 
Randomized control trials (RCTs) are considered the gold standard in determining if an 
intervention has a significant effect on an outcome. RCTs consist of two groups randomized to a 
single treatment arm. However, these two studies will use a crossover design. RCTs generally 
require a large sample size, which is not practical for these studies, whereas a cross-over model 
provides more information per participant because of their two treatments (conditions). The 
crossover model is also ideal because it allows for the same participants under both conditions to 
be compared. In other words, participants will serve as their own control, limiting confounding 
variables that would exist when comparing two different people. While this takes more time than 
RCTs, the within-subjects analysis controls for confounders that occur between participants. 
Hence, the changes in outcomes within conditions can be compared on the same person.  
For additional analysis and investigation into the physiological mechanism of interest, a 
separate trial will also take place: in this study, these participants will be recruited to repeat the 
same randomized conditions but while assuming a supine position. Exploratory data will be 
collected to make inferences on the effect of positioning during normal conditions (control) 




This study sought to investigate arterial stiffness as a main outcome, but also intended to 
evaluate several parts of the conceptual model shown in Figure 1. Hemodynamic changes in 
preload, afterload, and inotropy were examined. Additionally, peripheral stiffness measures and 




Arterial stiffness (AS) is a condition marked by reduced elasticity and compliance in the 
arteries. As a primary outcome, this measure will be used to evaluate acute vascular changes in 
the distensibility for the arterial wall as a result of PS. AS has been shown to be predictive of 
CVD risk and is associated with hampered coronary perfusion, higher myocardial afterload and 
left ventricular hypertrophy .37,49–51 In addition to its association with CVD outcomes, AS has 
significant prognostic value because it is one of the earliest detectable manifestation of 
diminished function and adverse structural changes in the vessel.52 In a longitudinal study of 
1500 patients, aortic AS was more predictive of stroke, CVD, and death from CVD outcomes 
than smoking.51 Indeed, AS is a measure that should be considered in the context of adverse 
CVD outcomes. 
The gold standard of measuring AS is measuring the aortic pulse wave velocity (aPWV), 
i.e., the speed it takes from a pulse wave to travel from one point on a proximal aortic segment to 
the distal point of the aorta.52 AS produces a faster aPWV because compliance in the arterial wall 
allows the forward wave to move quickly through the artery. The relationship between PWV and 
the percent diameter distensibility of the arterial wall can be modeled by  𝑑𝑖𝑠𝑡𝑒𝑛𝑠𝑖𝑏𝑖𝑙𝑡𝑦 =
(3.67/𝑃𝑊𝑉)2 . Therefore, with reduced percent distensibility, the PWV increases 
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proportionally.52,53 Many devices measure aPWV, including oscillometric devices, where the 
proximal and distal pulse waves are detected by two cuffs. One such device widely used by 
researchers is the VICORDER®, a device that produces valid measures against magnetic 
resonance imaging (MRI) measurements for aPWV.54 Previous studies show that the 
VICORDER® is repeatable between and within observers.55 The VICORDER® is much less 
expensive and time-consuming than MRI and does not require certification to operate.  
SphygmoCor XCEL is a tonometry device that was also considered to be used in the 
study. It is validated for aPWV values and has the technology to derive central hemodynamic 
measures from aPWV values in a technique known as pulse-wave analysis (PWA). Like the 
SphygmoCor XCEL, the VICORDER® is capable of PWA. These additional hemodynamic 
measures, including central systolic blood pressure (cSBP) and augmentation index (AIx), 
provide additional data regarding the cardiovascular health of the participant for further analysis. 
However, SphygmoCor EXCEL requires training with the tonometer device to obtain a carotid 
waveform, which can be technically challenging and time consuming. The VICORDER® is the 
ideal device to use in this study as it simpler to use. Additionally, to maintain participant privacy, 
the VICORDER®’s two cuffs can be applied over clothing. 
Venous Pooling 
VP can be detected by increases in calf circumference. Using a tape measure to record 
calf circumference is a low-cost and simple method that has been used in previous studies. Near-
infrared spectroscopy (NIRS) is a technique also used to monitor lower leg blood volume in PS 
studies.31 The NIRS device (PortaLite, Artinis) estimates muscular perfusion by measuring 
relative changes in total hemoglobin (tHB) based on the sum of deoxygenated (HHb) and 
oxygenated hemoglobin (HbO2).
45 Finally, observing the changes in venous distention, measured 
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by the change in the vein’s diameter, confirmed increases in lower limb pooling. Veins, having 
thinner walls and a high capacitance, can distend up to 18 times that of arteries.56 Logically, an 
increase in vein diameter will indicate an increase in fluid volume (pooling) in the distal limbs. 
Additional Measures 
Sympathetic nervous response was observed through skin temperature and galvanic skin 
sensitivity using a physiology monitoring vest. Transcutaneous Doppler measurements evaluated 
SVR to detect changes in vascular resistance, which increases with sympathetic response. 
Ultrasound was used to measure other hemodynamics, including MAP, central systolic blood 
pressure (cSBP), SV and CO, to support or challenge the conceptual model. 
Internal Validity 
Internal validity is preserving the integrity of the study by ensuring the dependent 
variables are measured without exogenous influence. This project strove to maintain internal 
validity by standardizing procedures for each participant, thereby limiting confounders. To the 
best of ability, the conditions under which testing will take place were as consistent as possible. 
All testing took place in the UNC Cardiometabolic Lab (CML) which has consistent 
environmental conditions. Humidity and ambient temperature were noted at each visit to ensure 
that no uncomfortable conditions are present. To further control exogenous variables, 
participants had pre-visit guidelines, as detailed in Table 2; Interviews took take place prior to 
testing to ensure participant compliance. To limit confounding variables, stimulants, depressants, 
food, exercise were restricted and scheduling the participants took place at a similar time during 
the morning. Female participants in the prolonged sitting group had their menstrual cycle 
controlled for the follicular phase to minimize any hormonal impact of estradiol on vascular 
response. Lastly, experimental visits took place within 1 week of each other, allowing for the 
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prior treatment to wash out while to limit variations in stress, hormones, and other physiological 
factors. Improving the study’s internal validity ensured the results are factually sound. 
Consideration Explanation Control Procedure 
Physical activity prior to 
sitting may improve 
endothelial function.39 
Prevent PA prior to testing to 
control for changes in 
vascular function. 
Reminder sent to all 
participants to refrain from 
exercising 24 hours prior to 
testing 
Caffeine and alcohol 
consumption potentially can 
heart rate and hydration 
Prevent consumption of 
caffeinated and alcoholic 
drinks  
Reminder sent to all 
participants to refrain from 
caffeine/alcoholic 
consumption 12 hours prior 
to testing 
Variability in meal 
consumption alters 
physiology. Insulin can 
induce nitric oxide production 
and controls ET-1 
expression.43 
Ensure no data confounding 
by diet or mealtimes. 
Reminder sent to all 
participants to fast for 8 hours 
prior to testing 
Estradiol levels impacts nitric 
oxide production (and thus 
vasodilatory response).57 
Prevent confounding by 
changes in hormone levels, 
such as during ovulation. 
Test female participants 
during follicular phase of 
menstrual cycle. Ensure both 
visits occur during this phase. 
Acute sleep deprivation is 
associated with increased 
AS.58 
Insufficient sleep prior to 
study could augment AS 
measurements. 
Remind participants to get at 
least 7 hours of sleep prior to 
study. 
Table 2:  Procedures to control internal validity in participant recruitment and testing. 
 
Population/ Sampling 
Healthy adult individuals, middle-aged and younger, will be recruited to maintain internal 
validity (Table 3). Recruitment methods will include social media postings, email circulation on 
college list-servs and paper postings on local billboards. The variety of media will give the study 
more exposure to a wider diversity of people. To be eligible, a participant must be between the 
ages of 18 and 45 years. AS increases with increasing age59, as do many cardiovascular 
comorbidities that affect vasculature, e.g., type 2 diabetes and hypertension. Therefore, 
establishing age as a criterion better supports recruiting sample with good arterial compliance. 
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 To further remove the possibility of confounders, additional criteria to exclude 
participants have also been established (Table 3). Individuals who have cardiometabolic diseases 
will be excluded, as well as those who take medications that affect the cardiovascular system. 
Nicotine products, including cigarettes and e-cigarettes, increase AS, blood pressure, and 
oxidative stress.60 Hence, individuals who smoke and vape will be excluded from the study. 
Criteria Method Rationale 
Age 18-45 y Screening interview Arterial stiffness and many comorbidities 
increase with age. 
Smokes or vapes Screening interview May have inflammatory processes or 
occult pathology occurring in vessels that 






hypertension and diabetes. 
Pathology altering vasculature will distort 
results. 
Prescribed or other 
drugs that affect 







blockers, and metformin. 
Drugs that alter blood pressure, heart rate 
and/or otherwise augment cardiovascular 
processes can confound results. 
Table 3: Eligibility and exclusion criteria. 
 
Biological Factors 
This study will not be exclusionary to any individual based on sex nor race/ethnicity 
during recruitment. The aims do not include examining sex-based differences of VP, nor 
hemodynamic or vascular outcomes. However, trends between sexes will be examined for future 
study. 
 
External Validity / Generalizability 
External validity is the ability for associations, trends, or significant conclusions from the 
study sample to be applied to a general population. This project emphasizes internal validity by 
keeping the sample homogenous to best control for external factors, limiting the ability to 
generalize to those outside the recruitment criteria. The selected sample of heathy participants 
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aged 18-45 years will best model VP after an acute bout of sitting to better understand its effect 
on normal vasculature. A healthy sample will better control for confounding variables including 
age, hypertension, and atherosclerotic disease, all of which can distort hemodynamics and 
arterial stiffness measures61. While the results may not be extrapolated to older individuals or 
those with vascular disease, they provide a good foundation for additional studies in higher risk 
populations. 
STATISTICAL CONSIDERATIONS 
Several analytical processes were considered for the data: Paired t-tests would not be 
suitable for the various conditions applied to participants in the study.  Another possible test to 
account to varying factors would be a mixed model Analysis of Variance (ANOVA), which 
would allow data between-subjects and within-subjects to be examined; however, an ANOVA 
does not allow for adjustments of co-variates. Linear mixed models can be adjusted for 
covariates and incorporate fixed and random effects, making it an ideal statistical analysis for 
this study. Linear mixed models were used to observe for differences within-subjects for the 
primary outcome (bfPWV) and secondary outcomes (calf circumference, venous distension, 
central systolic blood pressure and augmentation index). Statistical analysis examined these 
outcomes within the conditions applied to each group. In addition, baseline measurements were 
compared to post-testing results for outcomes of interest. Pearson’s correlation coefficients were 
used to examine the strength of relationships between outcome measures. Descriptive statistics 






Why is this study needed? 
• Sedentary behaviors, including prolonged sitting, are a widespread and hazardous 
problem among developed countries. 
• The link between CVD and sedentary behaviors is well established, however the 
physiological process that results in this increased risk is not known. 
• There is a need to understand the process involved in prolonged sitting. This knowledge 
can be used to investigate appropriate methods to interrupt the hazardous mechanism. 
What is known 
• Venous pooling occurs during prolonged sitting. 
• Arterial stiffness increases both centrally and peripherally after prolonged sitting. 
• Reduction in popliteal blood flow, and hence a reduction in shear stress and subsequent 
endothelial dysfunction, is caused by prolonged sitting. Endothelial dysfunction is 
essential in the vasodilatory function of blood vessels. 
What is not known 
• It is not known if venous pooling alone or in conjunction with other related components 
is the driving force behind increased arterial stiffness in the context of sitting. 
• It is not known if manually augmenting venous pooling will result in a dose-dependent 






• It is critical to understand why sitting increases the risk for cardiovascular disease since 
heart disease is the primary cause of death worldwide. About 50% these deaths could be 
prevented with appropriate lifestyle changes. 
• These lifestyles changes ought to be guided by evidence-based, scientifically sound and 
practical methods to reduce CVD. 
• Having specific times and procedures to break up prolonged sitting and counteract the 





CHAPTER III: METHODOLOGY 
 
 Ethical approval was obtained by the University of North Carolina at Chapel Hill 
Institutional Review Board. All participants provided written informed consent. Additionally, 
this study was in accordance with CONSORT (Consolidated Standards of Reporting Trials) 
guidelines. 
PARTICIPANTS 
Twelve adults from the Chapel Hill area were recruited for the study, with one dropping 
out for a total of eleven tested participants. Exclusionary criteria included any known cardio-
metabolic disorders, smoking/vaping, and taking medication known to affect cardiovascular 
function. 
EXPERIMENTAL DESIGN 
These two randomized crossover trials were designed with two postures (SIT and LAY). 
Each study had two conditions (CUFF and NON-CUFF). The LAY trial consisted of 6 
participants who laid supine during testing. The SIT trial recruited 6 participants who remained 
in a seated position during testing. Each position group had two experimental visits with a 
randomized condition applied during each visit. The CUFF condition involved the application 
and inflation of bilateral occlusive cuffs on the participants’ legs to induce VP. The NON-CUFF 
condition had cuffs with no pressure applied and was used as a control condition for the same 
posture.  Figure 2 illustrates the crossover design as it pertains to each study.  
 
23 
For each participant, an initial familiarization session took place for anthropomorphic 
measures and introduction to the equipment. This session took place prior to the experimental 
visits where the randomized conditions were applied.   
 
Figure 2: Crossover design with randomization of first visit condition. LAY and SIT trials were conducted 
separately. 
 
PREASSESSMENT GUIDELINES AND FAMILIARIZATION 
The initial visit involved participants being screened for pre assessment guidelines as 
well as health habits and pre-existing conditions in case these were missed in recruitment 
screening. The eligible participant then completed his or her informed consent. Anthropomorphic 
measures were obtained, and participant was fitted for the appropriate Equivital vest size for use 
in the later sessions. Body measures for VICORDER transit times were also taken and recorded. 
This visit allowed the participant to become acclimated with the testing center, researchers, and 
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devices, therefore alleviating physiologic changes that come with the anticipation of novel 
environments. 62 Taking these measurements and fittings also made experimental visits shorter 
and more efficient. 
EXPERIMENTAL VISITS 
The timeline for testing and measurements is illustrated in Figure 3. All participants 
arrived having fasted from food, alcohol, and caffeine and abstained from vigorous exercise for 
at least 24 hours prior to the visit. Each participant was fitted with an Equivital EQ02+ 
LifeMonitor vest to monitor EKG, galvanic skin response (GSR), and skin temperature. They 
then rested in a supine position for 20 minutes on an Armedica AM353 Hi-lo Treatment Table 
(Tiger Medical, TIGER#TM83695). During this rest period, VICORDER® cuffs were applied to 
the thigh, bicep, and ankle on a randomly selected leg. Calf circumference was recorded at the 
widest point of the gastrocnemius on the ipsilateral leg. For pilot testing, the PT vein was 
identified, and its diameter measured via ultrasound. The NIBP (Finapres) was applied to the 
second digit on the hand. Contralaterally to the NIBP side, the NIRS probe was applied to the 
participant’s medial gastrocnemius. Discrete baseline measurements of calf circumference, 
bfPWV, faPWV, MAP and PWA obtained from the VICORDER. A Doppler probe from 
Ultrasonic Cardiac Output Monitors (USCOM) was applied to locate a pulse signal at the level 
of the suprasternal notch to capture hemodynamic measures. This device was also utilized to 
measure preload by examining SV and stroke volume variation, the percent different in SV in 
between beats. Additionally, the USCOM measured inotropy using Smith Madigan Inotropy 
Index (SMII) as well as CO. Continuous HR measure from the NIBP was used for analysis.  
Immediately prior to testing commencement, the SIT participant was moved passively 
from their resting position to an upright position as researchers adjusted the table. The 
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participant’s position allowed the participant’s knees to bend approximately 90 degrees and the 
table height was adjusted so that the participant’s feet touched the floor. This passive movement 
allowed the research team to sit the participant upright without the participant engaging muscles 
that could alter blood flow from the lower limbs. The occlusive cuffs were inflated to 80 mmHg 
in the CUFF condition. The SIT participant then completed 120 minutes of uninterrupted sitting 
without occlusion (SIT NON-CUFF) or with occlusion (SIT CUFF).  The participants watched 
the same selection of non-stimulatory home improvement shows on an iPad to pass the time. 
After testing, the measurements obtained at baseline were repeated after the patient was placed in 
a supinated position. 
In the other trial, the LAY participant remained in a flat position for 120 minutes during 
testing either without occlusion (LAY NON-CUFF) or with occlusion (LAY CUFF), with the 
iPad positioned above the table they could watch the same shows as the SIT group during the 
supination period. 
Testing took place in the morning between 5:30 am and 8:00 am to control for variation 
among participant activities during the day. The two experimental visits were conducted within 7 









Figure 3: Design for the A) SIT study and B) LAY study. Both involve 20 minutes of resting in the supine 
position occurs prior to the beginning of testing to allow the participant to relax for accurate baseline 










Arterial stiffness refers to the distensibility of the arterial wall and is best quantified using 
PWV. PWV was measured along two separate arterial segments using the VICORDER® cuff 
system: brachial-femoral PWV was used to measure the aortic stiffness and femoral-ankle PWV 
assessed peripheral arterial stiffness. PWV values from two separate segments were recorded 
because pulse waves propagate (accelerate) in the distal arterial tree.63 Femoral-ankle PWV can 
give insight into pulse wave reflection, which, if timed during late systole, can increase 
afterload.64 Identifying variations between central and peripheral PWV can also give information 
about the systemic versus local vascular adaptations to PS.  The bfPWV was also be used in 
PWA to generate cSBP and AIx. AIx, along with faPWV and SVR, will quantify afterload, a part 
of the conceptual model described earlier in Figure 1.  
VP is the process of blood collecting in the legs. In this study, VP was an independent 
variable that will be induced as well as augmented; therefore, it is also considered an outcome. 
To accurately track its changes with sitting and with occlusion, two measures of VP took place: 
calf circumference as measured with a tape measure and calf hemoglobin content as measured by 
NIRS.  
Aortic shear stress is difficult to measure without the use of magnetic resonance. 
Therefore, to estimate decreases in blood flow and subsequent decreases in shear stress, CO was 
used as a surrogate measure to approximate changes in aortic blood flow. With USCOM, SV and 
CO can be reliably determined from the flow profile and the valve cross-sectional area (CSA).65 
Flow velocity can be calculated from the volumetric flow rate equation 𝑣 =
𝑄
𝑎
, where Q is 
cardiac output, a is aortic valve CSA and v is the flow velocity. Aortic wall shear stress can then 
be estimated from Poiseuille’s law: 𝛾 =  
2 (2+𝑛)𝑣
𝑑
 where γ is wall shear stress, d is internal arterial 
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diameter, v is time-averaged blood flow rate velocity and n is the velocity profile (in this case, n 
= 2 for a parabolic profile) 
To further investigate the components of the model, the SMII was measured using the 
USCOM to assess changes in inotropy. SMII describes the total power transferred from the left 
ventricle to the aorta with respect to the person’s body surface area.66 Inotropy is dependent on 
preload per the Frank-Starling mechanism but is influenced by a wide range of hormones, 
number of contractile units (muscle fibers) in the myocardium, and calcium uptake by 
myocytes.67 Inotropy, to our knowledge, has not been reported on in the context of venous 
pooling nor sitting, so this study seeks to elucidate if myocardial contractility changes under such 
conditions. 
Sympathetic nervous response was observed through three measures: skin temperature, 
GSR, and SVR. Because these three parameters are associated with circulating 
catecholamines,68–70 it is purported that prolonged sitting, especially with increased VP, triggers 
a higher sympathetic nervous system response.21 
Independent Variable: Venous Pooling 
Venous pooling is the manipulated variable in the study; therefore, it is critical that its 
presence and magnitude be documented. The study had two measures indicated to track VP: calf 
circumference and NIRS. Calf circumference, a surrogate measurement for VP9, was recorded at 
the widest part of the participant’s calf muscles prior to and after the testing session. Swelling in 
the calf indicates the increase in lower leg volume. NIRS indicates VP by continuously 
monitoring the changes in HHb and tHB in the gastrocnemius.  
During pilot testing, the dilation of the PT vein was measured in six participants. 
Considered to be a deep vein, the PT vein runs superficially at the medial malleolus and is 
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relatively simple to locate using ultrasound. 71. Cuffs were placed bilaterally just superior to the 
patella and inflated. After testing various pressures, 80 mmHg was found to increase PT vein 
diameter after 30 minutes of sitting in all pilot participants. This testing allowed the research 
team to confidently proceed with the full experiment knowing that VP was induced with sitting 
with a specific cuff pressure. 
Dependent Variable: Central Arterial Stiffness 
Central arterial stiffness was measured using bfPWV via the VICORDER® (SMT 
Medical) device. The VICORDER® has been validated for bfPWV and is commonly used 
among researchers to measure aortic stiffness.72 PWV (m/s) was calculated by dividing the 
arterial path length (D) by the pulse transit time (TT) between the brachial artery and femoral 
artery. Transit time was calculated by the VICORDER® software’s proprietary algorithm which 
measures the time between the foot of the proximal pressure waveform to the foot of the distal 
pressure waveform. For bfPWV, the proximal arterial site is measured at the brachial artery and 
the distal arterial site is measured at the femoral artery. 
Pressure waveforms were simultaneously captured using these volume displacement 
cuffs (Hokanson, Bellevue, WA) at the brachial artery (proximal site) and femoral artery (distal 
site). A 1 m/s increase in aPWV is associated with 7% increase in CVD, a clinically meaningful 
change. However, this is based on a meta-analysis with long-term studies, and therefore in an 
acute setting we would not anticipate such a large change.38  
This study elected to use bfPWV measurements instead of carotid-femoral PWV due to 
transcranial measures also being studied on the participant; cfPWV requires the use of a balloon 
being placed on the neck which would interfere with additional measurement outcomes (e.g., 
blood brain flow) that were a part of this study. Additionally, the carotid balloon is prone to 
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artifact due to its proximity to the jugular vein and is often cited as a discomfort for participants 
when it is inflated.73 Values obtained over the brachial-femoral path are closely correlated with 
those from the carotid-femoral path, therefore the validity of aPWV will be preserved. 
RANDOMIZATION  
The randomization procedure was performed by a research team member. Participants 
were first recruited to the LAY study first due to simpler application of devices and 
measurements. This group also served as quality control. For SIT and LAY, the order of cuff 
conditions was randomized prior to the familiarization session using an online randomization 
software (www.randomizer.org). The leg on which the VICORDER®, NIBP, and calf 
circumference will be measured were also randomized prior to testing, while the NIRS probe 
was applied to the opposite leg. 
SAMPLE SIZE  
The software program G*Power 3.1 (Heinrich-Heine-Universität Düsseldorf, Germany) 
was used to determine the minimum sample size using the ANOVA function. The calculation 
used an α-level of 0.05 for significance and effect size f= 0.25 for bfPWV and power (1-β) = 0.8. 
The output was n = 12 participants, however, to be conservative, we elected to increase the 
sample size to 16 participants.  This also allowed for flexibility for unexpected loss-to-follow up 
or the ability to remove unreliable data measures without compromising statistical power. 
QUALITY CONTROL 
For a given outcome, all measurement and analysis were conducted by a single observer. 
At the start of the study, the first three data sets were checked by an independent observer. Only 
VICORDER® waveforms free of significant artifacts were recorded for bfPWV and faPWV 
measurements; this was to ensure accurate pulse wave transit times. Further, each participant’s 
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anatomical distances, used to calculate PWV between cuff sites, were measured by a single 
observer to reduce error. 
DATA MANAGEMENT AND STATISTICAL ANALYSIS 
Paper data collection sheets were stored in a locked drawer and backed-up as a digital 
copy on two laboratory computers. The α-level was set a priori at 0.05 for main effects and 0.10 
for interaction effects. Descriptive statistics and mechanistic outcomes were collected to compare 
similarities amongst the sample group. Statistical procedures were completed with Jamovi v1.6, 
where mixed linear models were used to compare outcomes within participants over time and 
within conditions for each trial. Effect sizes were calculated as Cohen’s d, where ≤ 0.2, 0.2, 0.5, 
and 0.8 were defined as trivial, small, moderate, and large effects, respectively. Arterial stiffness 
is pressure-dependent; thus, the data were adjusted for MAP during statistical analyses of 
PWV.74 In addition to MAP, all hemodynamic measures and pulse wave velocity measures were 





CHAPTER IV: RESULTS 
 
PARTICIPANTS 
Participants were recruited for the SIT trial between March 16th and April 8th, 2021, 
through posters adverts, emails, and short presentations to classes at UNC Chapel Hill. Eleven 
participants were screened for eligibility; three could not meet the scheduling demands of the 
study and two declined to participate (Figure 4). Six participants were enrolled in the study, of 
which five completed the three visits (23.6 [5.3] y, 40% F, 23.1 [3.2] kg/m2). One participant 
was dropped due to a vasovagal pre-syncopal episode during the second visit; no data for this 




Figure 4: CONSORT diagram for recruitment and testing of the LAY and SIT trials. bfPWV, brachial 
femoral pulse wave velocity; NIRS, near-infrared spectroscopy. 
 
Participants were recruited for the LAY trial between February 15th and March 15th, 
2021, through email and GroupMe recruitment efforts among staff and students at UNC Chapel 
Hill. Eleven participants were screened for eligibility; four did not enroll: three did not meet 
eligibility criteria and could not meet the scheduling demands of the study. Six participants (26.5 
[7.6] y, 66.7% F, 22.5 [2.3] kg/m2) completed the three visits. One participant was excluded from 
the post measurement analysis for the NIRS outcomes due to aberrant data from the NIRS probe. 
HARMS 
Our twelfth participant, who participated in the SIT trial, suffered a vasovagal episode. 
After sitting for approximately 30 minutes with the cuff inflated, the participant alerted the 
researchers that she was feeling lightheaded and unwell. After deflating the cuffs and placing her 
 
34 
in a Trendelenburg position, she felt relief within minutes. She stated that pre-syncopal episodes 
are not unusual for her, including after fasting. No serious harm resulted; however, the 
researchers discontinued her study for her continued safety. 
SIT TRIAL 
Venous Pooling 
 Venous pooling (VP) served as the manipulated independent variable. A significant 
interaction effect was present in calf circumference (p = 0.001) with a very large effect noted (d 
= 3.41 in the CUFF group, Figure 5A). Calf circumference increased across over 120 minutes of 
sitting, by 3.69% in the CUFF (β= 1.34, CI 95% 1.15 to 1.51) group and by 0.25% in the NON 
CUFF group (β = 0.088, CI 95% -0.08 to 0.26, d = 0.224). VP was also quantified by NIRS 
measures. For HHb, no interaction effect was found; however, a condition effect was present (p 
= 0.075): HHb increased in the CUFF condition but did not change in the NON CUFF condition 
(Figure 5B). The effect size for HHb was moderate (d = 0.558). In summary, VP increased in 
both sitting conditions. The data show a greater magnitude of pooling in the CUFF condition due 








NON CUFF β = 0.088, CI 95% -0.08 to 0.26 




β = 18.4, CI 95% 3.56 to 33.2 
 
 
Figure 5: Mean SIT trial calf circumference (5A) and HHb (5B) over time and by condition 
with SE bars. HHb increased in the CUFF condition significantly. Calf circumferences both 
increased over time but more in the CUFF condition. Cuff, condition with compression by 
inflated cuffs; Non cuff, control condition; Pre, prior to 120 minutes sitting; Post, after 120 
minutes sitting; HHb, deoxygenated blood; SE, standard error. 
 
Arterial Stiffness 
No significant interaction effect was found for bfPWV during the SIT trial (p = 0.280) 
and no condition nor time effect was present. Brachial femoral PWV showed nonsignificant 
increases in both CUFF and NON CUFF after 120 minutes of sitting (p = 0.349 and 0.196 for 
condition and time effects, respectively), The mixed model plots, adjusted for MAP and 






 Condition β = -2.06, CI 95% -3.77 to -0.36 
Time β = 0.18, 95% CI: −0.40 to 0.43 
 
Figure 6: Changes in bfPWV (m/s) over 120 minutes in the SIT group. Slope for condition and time 
shown in upper right corner. brachial-femoral pulse wave velocity; CUFF, condition with 
compression by inflated cuffs; NON CUFF, control condition. 
 
 
Secondary Outcomes  
Preload and Cardiac Output 
Preload was measured using SV and stroke volume variation (SVV) measures (Table 4). 
SV did not show a significant change in the SIT trial (p = 0.677 for condition and p = 0.981 for 
time) despite changing in opposing directions among the two conditions, increasing in the NON 
CUFF but decreasing in the CUFF condition. SVV increased in the CUFF condition and 
decreased in the NON CUFF condition.  
An interaction effect was observed in CO, which decreased 4.60 % in the NON CUFF 
condition and 13.49 % in the CUFF treatment (p = 0.057) with a small to very large effect size 
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(d= 0.465 and d = 1.37, NON CUFF and CUFF, respectively.) HR was also found to have 
decreased with an interaction effect and with a large effect size (p = 0.020, d= 0.580).  
 
SIT condition 
  CO SV SVV HR 
Time L/min mL % bpm 
Cuff Pre 4.7 (0.47) 78.8 (13.69) 16.5 (6.04) 59.7 (9.06) 
  Post 4.4 (0.76) 74.9 (15.47) 20.5 (5.00) 59.4 (8.71) 
Non-Cuff Pre 5.2 (1.13) 71.4 (17.54) 57.3 (31.79) 75.2 (8.82) 
  Post 4.6 (0.99) 75.1 (19.29) 34.4 (22.78) 62.9 (8.98) 
Condition        
  β -0.201 -1.45 -0.449 -3.18 
  P 0.152 0.677 0.811 0.18 
  ES -0.337 0.094 0.054 -0.559 
Time        
  β -0.395 0.083 -3.18 -7.65 
  P 0.005 0.981 0.073 <0.001 
  ES 0.763 0.006 0.424 0.954 
Interaction        
  β -0.488 -0.83 -4.56 -9.30 
  P 0.057 0.903 0.123 0.020 
  ES 0.471 0.028 0.302 0.580 
Table 4:Arterial stiffness parameters and central hemodynamics in the SIT trial presented as mean (SD) 
(n = 5). CO, cardiac output; SV, stroke volume; SVV, stroke volume variation; HR, heart rate. 
 
Afterload, Inotropy and Sympathetic Response 
Table 5 summarizes the observed changes in measures that impact afterload and 
contractility. MAP had an interaction effect (p = 0.026) present: In the CUFF condition, MAP 
increased by 4.33% (β = 4.30) with a strong effect size (d = 0.795). In the NON CUFF condition, 
MAP showed hardly any change (-0.07%, β = -0.03) with a trivial effect (d = 0.01) Additionally, 
a significant interaction effect for cSBP was present, where blood pressure increased in the 
CUFF condition by 4.03% (β = 5.00, d = 1.23) and by 0.15% in the NON CUFF condition (β = 
0.19, d = 0.05). A condition effect for AIx was observed as well (β = -7.69) with a large effect 
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present (d = 0.654). faPWV decreased in the CUFF condition and did not change in the NON 
CUFF condition, but these changes were not statistically significant. 
In the SIT trial, evidence of elevated sympathetic response was present: a significant 
interaction effect was present in skin temperature (, p < 0.001). Skin temperature increased by 
2.06% and 6.22% in the CUFF (β = 0.724) and NON CUFF (β = 2.18) groups, respectively. The 
simple effect sizes were small in the CUFF condition (d = 0.344) and very large for the NON 
CUFF group (d = 1.05). Further, GSR had a condition effect present (β = 3.44, p = 0.020) and 
SVR was found to have a significant time effect (β = 172.3, p = -0.032).  Inotropy, or the 
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Condition           
  β 3.44 0.517 84.8 0.396 -0.018 -2.06 2.38 -7.69 
  P 0.020 0.139 0.700 0.431 0.912 0.035 0.025 0.096 
  ES 3.13 0.349 0.333 0.328 -0.019 0.531 0.582 0.654 
Time           
  β 1.28 1.45 172.3 -0.164 0.206 2.12 -2.41 1.05 
  P 0.317 <0.001 0.032 0.711 0.200 0.030 0.023 0.186 
  ES 0.217 0.980 0.719 0.075 0.218 0.55 0.593 0.090 
Interaction           
  β -4.17 1.45 46.7 0.259 0.358 -4.36 4.442 -14.3 
  P 0.113 0.045 0.860 0.777 0.272 0.026 0.040 0.119 
  ES 0.758 0.490 0.097 0.065 0.274 0.569 0.512 0.614 
Table 5: Afterload, inotropy and sympathetic nervous system parameters in the SIT trial, before and after 
conditions applied. Reported as mean (SD). GSR, galvanic skin sensitivity; skin temp, skin temperature; 
SVR, systemic vascular resistance; SMII, Smith-Madigan Index; MAP, mean arterial pressure; faPWV, 
femoral ankle pulse wave velocity. 
 
LAY TRIAL 
Venous Pooling (LAY) 
Venous pooling was evident in the LAY trial in both the calf circumference measures as 
well as the NIRS outcomes. Figure 7A shows that a significant condition effect was observed in 
calf circumference in the LAY trial (β = 0.074, p = 0.016), demonstrating a 0.22% increase in 
calf size.  
Output from the NIRS device on the gastrocnemius provided additional insight on VP 
(Figure 7B). HHb was found to have a condition effect (β = 12.70, p = 0.010), increasing by 
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37.00% and 24.90% in the CUFF and NON CUFF treatments, respectively. The effect of the 
tourniquet cuff shows that the occlusive treatment successfully increased pooling in the legs, 
even while the participants were supine. 
A) 
Condition effect: 
 β = 0.074, 95% CI: −0.46 to 0.61 
B) 
Condition effect: 






Figure 7: LAY trial calf circumference (7A) and HHb (7B) over time and by condition. HHb 
increased in the CUFF condition significantly. Calf circumferences both increased over time but 
more in the CUFF condition. CUFF, condition with compression by inflated cuffs; NON CUFF, 
control condition; Pre, prior to 120 minutes lying flat; Post, after 120 minutes of lying; TSI%, 
tissue saturation index.  
 
Arterial Stiffness (LAY) 
Following adjustment for MAP and baseline measures, an interaction effect was observed 
for bfPWV (NON CUFF β = -0.361, CUFF β = 0.305, p = 0.044) with small effects observed 
(NON CUFF d = 0.481; CUFF d = 0.283), shown in Figure 8. Brachial-femoral PWV increased 
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in the CUFF group by 5.44%. Conversely, the NON CUFF group showed evidence of decreasing 
central arterial stiffness (- 6.43%) as bfPWV slowed. 
 CUFF β = 0.305 95% CI: −0.13 to 0.74 
NON CON β = - 0.361 95% CI: −0.66 to -0.06 
 
Figure 8: Changes in bfPWV (m/s) over 120 minutes LAY group. Interaction effect slopes shown for 
each condition, upper right corner. bfPWV, brachial-femoral pulse wave velocity; CUFF, condition 
with compression by inflated cuffs; NON CUFF, control condition. 
 
Comparisons to SIT Trial 
Like in the SIT trial, there was no significant change in SV. However, in the LAY trial, 
CO decreased over time in the CUFF condition significantly (β = -0.475, p = 0.006) with a large 
effect size (d = 0.630), following a similar pattern as in the sitting condition. In contrast to the 
SIT trial, a significant small time-effect (β = -3.200, p = 0.073, d = 0.232) showed that SVV 
decreased over the course of the LAY trial.  
Afterload is affected by blood pressure and vascular resistance yet LAY yielded mixed 
results as whether it was substantially affected. MAP increased in the CUFF condition, which 
followed the same pattern as the SIT condition, but differs in that the result was nonsignificant (p 
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= 0.193). Mean SVR increased in both CUFF and NON CUFF, but no condition effect was 
detected; rather, a significant time effect was observed (β = 208, p = 0.031), with a small effect 
size (d = 0.301).  
Peripheral arterial stiffness also influences afterload, as the reduction in artery 
compliance reduces buffering of the forward wave and sends it back prematurely, creating 
resistance in the left ventricle during systole. In the LAY study, the mean faPWV did not change 
in the CUFF condition but increased in the NON CUFF condition over time, although this 
change was nonsignificant. The SIT study also did not find statistical significance in faPWV. 
With regards to sympathetic activity, skin temperature and GSR increased in CUFF and NON 
CUFF, but these changes were nonsignificant, a contrast to the significant increases in these 
measures in the sitting trial. AIx and cSBP measures in the LAY trial were not usable in analysis 




CHAPTER V: DISCUSSION 
 
The main purpose of the SIT trial was to determine the acute effect of venous pooling 
manipulation on central arterial stiffness, i.e., investigate the changes in bfPWV after venous 
pooling from prolonged sitting (PS), and with cuff manipulation on both positions. The LAY 
study primarily served as quality-control: it allowed us to examine the effects of VP pooling and 
PS independently on bfPWV and secondary outcomes. These two trials provide insight as to 
whether VP is a driving force behind the deleterious effects of PS, i.e., elucidate the effect of 
increased VP on arterial stiffness in PS.  The main findings from the SIT study were increased 
VP and disrupted hemodynamics, notably decreased CO and increased SVR.  
LIMITATIONS AND STRENGTHS 
The participant eligibility criteria ensured that only young, healthy adults were recruited 
in the two trials. This improved internal validity of our measures by minimizing confounding 
variables (such as vascular disease), however, it cost external validity; in other words, the study 
is not as generalizable to a wider population. Another major limitation is the small sample size; 
some effects are present, but many are not statistically significant due to a dearth of power. 
Furthermore, a lack of literature on AS and VP in supine positions makes it difficult to compare 
changes in bfPWV and secondary measures in the LAY trial. While hemodynamics has been 
studied in supine patients, induced pooling while lying flat for long periods of time has not been 
examined in the literature to our knowledge. This novelty is a strength in contributing new data 
to arterial stiffness and hemodynamics in a supine position; however, it means that our data 
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cannot be compared to that of other studies. A strength of this study is that the protocol was 
standardized in both the SIT and LAY trials, i.e., internal validity was maintained. Both trials 
enacted the same strict pre-assessment guidelines to manage confounding variables. The SIT trial 
seeks to elucidate not just one piece of the conceptual model, but several, in order to strengthen 
the argument supporting the answer to the research question. Further, the LAY trial provides 
insight into venous blood in the lower limbs while supine, which no other experiment has 
examined, particularly one that seeks to induce VP.  
COMPARISON TO LITERATURE 
Pulse wave velocity, the gold standard measure for assessing arterial stiffness, was used 
to assess aortic stiffness and compare the values within-subjects to observe changes. In the SIT 
study, VP occurred in both CUFF and NON CUFF conditions. Hydrostatic pressure creates 
conditions favorable to VP while the lack of calf muscle pump diminishes venous return. In the 
CUFF condition, the bilateral occlusion further impairs venous return, so that the venous blood 
will remain in the lower limb veins. Our results for calf circumference in the SIT NON CUFF 
study were not as dramatic in comparison to other sitting studies, with an increase of only 0.25% 
(CI 95% -0.08, 0.26). Other PS studies ranging from 3 to 6 hours of sitting found 2.64-5.00% 
increases in calf size.7,9,27 However, supporting our hypothesis, VP was greater when occlusive 
cuffs impaired venous return, as calf size grew 3.69%, as compared to NON CUFF group 
(0.25%). Increases in HHb, including a 60.4% increase with cuff occlusion, further assert that 
more deoxygenated blood (i.e., venous blood) is remaining in the legs during PS. 
We found that bfPWV increased in both CUFF and NON CUFF by 5.07% and 0.54%, 
respectively, indicating that the central AS has increased, but only at nonsignificant probabilities 
(p = 0.280). In support of our hypothesis, inducing additional pooling resulted in stiffer arteries 
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than in the control sitting condition. While no other studies have induced VP using occlusion, 
our control condition (i.e., NON CUFF)’s change of 0.034 m/s in bfPWV shared the same 
direction of change compared with other findings in the literature, although it was a much 
smaller increase. possibly due to small sampling. Credeur et al. (2019) found a 0.4 m/s increase 
after 3 hours of PS in cfPWV, whereas Evans et al (2019) observed an increase of 0.3 m/s. We 
found similar increase in the SIT NON CUFF condition of 0.5 m/s, despite our study using 
bfPWV instead of cfPWV. 
This study aimed to elucidate the process between PS and AS, specifically between VP 
and AS. Our model theorizes that VP from sitting causes decreased CO and SV due to reduced 
filling pressures from lowered venous return. MAP, which relies on CO to maintain perfusion, 
must compensate for this reduction by increasing SVR29,35. Some of the data support this theory, 
as CO decreased from sitting and diminished more in the occlusive condition than in the control. 
SV also decreased in the CUFF condition, but without statistical significance, and therefore 
decrease in HR, rather than SV, may have driven the decrease in CO. A more powerful study 
sample will be needed to determine if this study’s small sample did not adequately capture a 
significant change or if whether SV does not change with VP, which would run contrary to the 
proposed model. 
Of note, SVR and MAP increased in both NON CUFF and CUFF; both measures are 
associated with increased PWV, therefore these data validate the last step of the conceptual 
model.75 It is theorized that PS increases sympathetic nervous activity,76 and MAP and SVR are 
upregulated by circulating catecholamines.56 Our data provides evidence of sympathetic 
stimulation through the increased GSR and skin temperature measurements after PS.   
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In comparison to other studies, several have also found decreased CO and SV after PS 
using electrical impedance plethysmograph or cardiac catheterization to estimate these 
parameters, whereas we used Doppler.26,77–79Regardless, the pattern of diminished CO after PS 
supports the theory that decreased venous return from VP affects the myocardial filling and 
ejection. Our findings with MAP contrasted with unchanged results in three sitting studies 
ranging from 3 to 4 hours of PS.6,7,80 However, one PS study by Shvartz et al. (1983) found 
increases in both SVR and MAP, and, though the latter was nonsignificant, aligns more closely 
with our findings.26   
It is important to recognize the importance of the LAY study as it pertains to quality 
control. The posture of sitting may be independently effecting the observed physiologic change, 
not just VP. Therefore, performing the same experiment in a supine position offers the ability to 
compare results between PS and prolonged lying, with inflated cuffs and without. While the two 
posture groups could not have a within-subjects analysis, the patterns from the outcomes are still 
valuable when considering other factors that could impact arterial stiffness from sitting, 
including the leg-bending posture.22 
To summarize, our data provide support for the hypothesis, as well as many parts of the 
conceptual model set forth in the literature review. The data show that bfPWV increased over 
120 minutes of PS and even more so with augmented VP. Furthermore, the results from the LAY 
trial show increased VP with the presence of occlusive cuffs. While AS increased, the changes 
were not statistically significant, likely due to a lack of power. Our findings provide evidence 
that VP plays a role in the arterial stiffening process, but certain details, such as whether CO 
changes are driven by HR versus SV, and whether PWV would significantly change in a larger 




It is well-known that PS is strongly linked to CVD3,13 but the process by which sitting 
results in this elevated risk is not understood. This remains a public health concern because 
American adults spend most of their waking hours seated,5,12 while CVD, a largely preventable 
disease, continues to be the primary cause of death in the US and worldwide.81 
 AS is a predictor of poor cardiovascular outcomes.38,82–84 While AS during sitting has 
been studied in the context of endothelial dysfunction9,85 and central hemodynamics7,10,45,47, the 
specific role of VP in AS has been understudied. It was not known if effects on AS and 
hemodynamics could be substantially altered with augmented venous pooling, nor if the physical 
position of the participant would impact these outcomes. Furthermore, it was not known if VP 
could be induced with occlusive cuffs. Table 6 provides a reiteration of the questions and 
knowledge gaps discussed in Chapter II along with the implications from this study added. 
This study provides evidence that VP plays a key role in AS and lends data to support a 
theoretical model that explains the physiology driving the process. With this information, 
strategies to interrupt PS can be targeted to specifically address VP so that the process can be 
hindered before deleterious hemodynamic effects and vascular stiffening occur. Current 
evidence-based guidelines addressing sedentary behavior are limited and vague.86 The American 
Heart Association concurs that investigations into public health interventions are needed, not 
only for methods that lower overall sedentary time, but ones that reduce mechanisms that lead to 
CVD outcomes87. Further, community-based and individual initiatives need data to support 
effectiveness prior to implementation. Examining ways to counteract VP may be a foundation in 





What did we know? 
• It was known that AS and PS contributes to CVD risk and that PS leads to increased 
AS. 
• Several studies in the literature have shown increased VP after PS. 
 
What did we not know? 
• VP’s effects on AS and hemodynamics during PS have been understudied. 
• It was not known if posture would impact VP induced by occlusive cuffs, nor whether a 
supine posture would alleviate increases in arterial stiffness or deleterious hemodynamic 
changes – or even have any physiological changes at all. 
What have we learned? 
• VP is a factor behind hemodynamics changes. 
• VP positively influences increased AS during PS. 
Why is this new information useful? 
• Young, healthy individuals are still susceptible to increases in lower limb pooling, 
central arterial stiffness, increases in afterload and decreases in preload. In other words, 
patterns associated with increased risk of CVD have been found in young people in as 
little as 120 minutes of sitting. 
What do we need to know next? 
• Research ought to be conducted on strategies that can be used to interrupt VP, and how 
much can they offset the detrimental influence of VP. 
• For CVD risk reduction from PS to be successful, the scientific community must 
investigate how to incorporate these strategies into the public’s lifestyles. 
Table 6: Summary of gaps in knowledge, discussion topics and future study. 
 
CONCLUSIONS 
Prolonged sitting leads to AS and CVD risk and is a public health concern requiring 
attention. To address this problem, it is first necessary to understand how PS leads to AS and 
consequently CVD risk. This study has shown that VP is a measure of interest, and not only is 
associated with increased bfPWV, but also has demonstrated undesirable hemodynamic changes 
in preload and afterload. Further, this study has provided evidence that increased VP leads to 
even more dramatic changes in these measures, both in supine and in sitting positions. This study 
demonstrates that VP should be examined more closely when considering sitting interrupting 
strategies. Additional investigation into how to best reduce VP in the lower limbs during PS may 
be the next step in reducing CVD risk in the general population.  
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APPENDIX A: CONSENT 
University of North Carolina at Chapel Hill 
Consent to Participate in a Research Study 
Adult Participants 
 
Consent Form Version Date: ______________ 
IRB Study # 20-3403 
Title of Study: The Role Of Blood Pooling In The Legs During Prolonged Sitting On 
Cardiovascular And Cerebrovascular Outcomes: A Mechanistic Study 
Principal Investigator: Alexander Pomeroy 
Principal Investigator Department: Exercise and Sport Science 
Principal Investigator Phone number: (919) 962-0396 
Principal Investigator Email Address: alexpom@live.unc.edu  
Faculty Advisor: Lee Stoner 




We are looking to examine the vascular, cerebrovascular, and executive function response to 
blood pooling in the veins of the lower limbs, a common side effect of prolonged sitting, with 
and without exposure to prolonged sitting itself. It is currently unknown whether (1) venous 
pooling has a role in systemic vascular health effects seen during prolonged sitting (2) whether 
venous pooling has a role in changes in blood flow to the brain and perfusion of the prefrontal 
cortex (3) whether venous pooling and the corresponding cerebrovascular changes affect 
executive function, and (4) what specific physiological pathways explain these changes. The 
devices used in this study are non-invasive and no known adverse events have occurred with use 
of the stated devices. The findings from this study may result in better understanding of how 
changes during prolonged sitting occur, and help elucidate potential strategies for reducing acute 
vascular, cerebrovascular, and cognitive dysfunction during prolonged sitting. The purpose of the 
study is to measure the changes in the heart, vasculature, brain perfusion and cognitive function 
caused by venous pooling in the legs from prolonged sitting.  
We seek healthy adults 18- 45 years of age, free of cardiometabolic disease, and who do not 
smoke nor vape. Pregnant women and those who take medications known to alter cardiovascular 
function are not eligible. A total time commitment of 305 min is required: the study consists of 
three visits, the first being a familiarization visit (45 min duration) and two experimental visits 
(130 min duration each). 
No significant risks will occur should you take place in this study. Your participation will benefit 
the scientific body on the changes that occur from prolonged sitting and venous pooling. There is 
no benefit to you for completing this study, however, we are happy to provide a summary of 
your results, including blood pressure, cardiac output, arterial stiffness, carotid blood flow, and 
cognitive measures, in comparison to group means after the completion of the study. 
 
50 
What are some general things you should know about research studies? 
You are being asked to take part in a research study.  To join the study is voluntary. 
You may choose not to participate, or you may withdraw your consent to be in the study, for any 
reason, without penalty. 
 
Research studies are designed to obtain new knowledge. This new information may help people 
in the future.   You may not receive any direct benefit from being in the research study. There 
also may be risks to being in research studies. Deciding not to be in the study or leaving the 
study before it is done will not affect your relationship with the researcher, your health care 
provider, or the University of North Carolina-Chapel Hill. If you are a patient with an illness, 
you do not have to be in the research study in order to receive health care. 
 
Details about this study are discussed below.  It is important that you understand this information 
so that you can make an informed choice about being in this research study.  
 
You will be given a copy of this consent form.  You should ask the researchers named above, or 
staff members who may assist them, any questions you have about this study at any time. 
 
What is the purpose of this study? 
The purpose of this research study is to (1) Explore the cardiovascular, cerebrovascular, and 
cognitive effects of venous pooling in the lower limbs during a bout of prolonged sitting, and (2) 
Explore the effects of venous pooling independently of prolonged sitting on cardiovascular 
function. 
 
Are there any reasons you should not be in this study? 
You should not be in this study if you have known cardiovascular or metabolic diseases (e.g. 
Congestive heart failure, peripheral artery disease, type I and II diabetes, etc.), you use tobacco 
or nicotine, take medications known to affect cardiovascular function (e.g. beta-blockers, ACE 
inhibitors) or you are pregnant. 
 
How many people will take part in this study? 
Approximately 22 people at UNC-Chapel Hill will take part in this study. 
 
How long will your part in this study last? 
Should you wish to participate in the study, you will be required to attend the Applied 
Physiology Laboratory at University of North Carolina at Chapel Hill on three occasions. The 
first visit will last approximately 45 minutes, and the CONTROL and CUFF visits last 
approximately 130 minutes. 
 
What will happen if you take part in the study? 
If you would like to take part in the study, you would be required to visit the Applied Physiology 
Laboratory at UNC, Chapel Hill on three occasions. See below for overall study design: 
Visit 1 - The first visit will be a familiarization session during which all experimental procedures 
will be described to you in full. You will provide informed consent before the study begins, then 
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complete a brief questionnaire on your medical history to ensure you are eligible for this study. 
Pregnancy tests will be done on all females who might be able to get pregnant at the start of the 
study. The research team will pay for these pregnancy tests. If you meet the requirements, we 
will then show you how each device is prepared for this study, how it functions and where it will 
be placed on the body for data collection. At the conclusion of the visit, we will take your 
baseline cognitive assessment for the study. The following devices will be used for study 
purposes:  
• Transcranial Doppler (TCD) – A headset snugly placed on top of the head. 
• VICORDER® – Non-invasive device using blood pressure cuffs to assess arterial 
health. 
• Ultrasound Probe – Small probe lightly placed over several arteries running up the 
neck to assess blood flow to the brain. 
• Near-Infrared Spectroscopy (NIRS) – Small probe (about 1 x 3 inches in size) 
placed on the calf. 
• Functional Near-Infrared Spectroscopy (fNIRS) – set of 8 probes (each about 2 
centimeters in diameter) mounted in a neoprene headcap. 
• Non-invasive Blood Pressure cuff (NIBP) – Device wrapped around the wrist 
with small cuffs encircling the middle and index fingers. 
• Equivital – Chest-worn device and strap that is placed on the skin under a shirt. 
• USCOM – small, specialized doppler ultrasound that is pressed just above the 
suprasternal notch (approximately where the neck meets the sternum) 
• Pupil Core – eye-tracking device worn like eyeglasses. 
This visit should take approximately 45 minutes. 
Visit 2 & 3 - During the experimental visits (CONTROL and CUFF), you will be required to rest 
quietly for a period of 10 minutes in a supine (lying) position. After, measures of cardiovascular 
function will be taken by the VICORDER® and Ultrasound devices. For the CUFF and 
CONTROL conditions, you will be asked to sit still and quietly for 2 hours while watching a 
non-stimulating documentary. Then, if seated, you will be passively shifted to a supine (lying) 
position where the VICORDER® and Ultrasound measurements will be taken again. At the end 
of the cardiovascular measurements in each experimental condition we will conduct a battery of 
cognitive tests.  
The cognitive tests involved in these two visits are called the Trail-Making Test (TMT) and the 
Verbal Fluency Test. In the TMT, you will complete two short puzzles on an iPad with your 
finger. You will be presented with numbers and letters placed semi-randomly. You will then 
connect 25 numbers and numbers, alternating between numbers and letters in numerical or 
alphabetical order. For example, one would connect “1” to “A”, then connect “A” to “2”, and “2” 
to “B” until 25 symbols have been connected. The VFT is a verbal test that also consists of two 
parts. In Part A, you will be given a category and instructed to name as many items in the 
categories as you can within 60 seconds. In Part B, you will be given a letter and will be asked to 
name as many words that begin with the letter as you can within 60 seconds. 
Prior to attending the Lab for visits 2 & 3, you will have to perform the following pre-assessment 
guidelines: 
• Fasted (> 12 hours), consuming only water. 
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• No caffeine consumption 12 hours prior to testing 
• No vigorous exercise 24 hours prior to testing. 
• No alcohol consumption 24 hours prior to testing. 
The total time commitment that will be required from you is approximately 305 minutes. 
Following the analysis of your data, we will happily provide a summary of your results in 
comparison to the group means. 
What are the possible benefits from being in this study? 
Research is designed to benefit society by gaining new knowledge.  You will not benefit 




What are the possible risks or discomforts involved from being in this study? 
The devices used in this study are non-invasive and there are no accounts of severe injury due to 
exposure to the stated devices. Physical harm due to participation in this study is likely very 
minimal: 
VICORDER® - The system requires the placement of pressure cuffs over several arteries for 
the collection of PWV/A data. Pressure cuffs will only be inflated underneath a level of 65 
mmHg. Physical harm or discomfort is unlikely and include, but are not limited to: 
Risk 1: Discomfort/unease: Infrequent (1 – 10%) – Application of a slight pressure over the 
carotid artery may impose a sense of unease for the participant. However, the light pressure used 
for this experimental protocol will in no way significantly damage cardiovascular structure or 
place the participant in danger. Investigators will make certain that communication on the 
procedures during testing session are clearly conveyed to the participant for comfort and safety.  
Near-infrared spectroscopy (NIRS): Risk of injury or discomfort is extremely low due to this 
device. Possible physical harms are, but not limited to: 
Risk 1: Eye damage/irritation: Rare (<1%) – Please do not, at any point, stare into the light 
emitted from the NIRS probe. 
Risk 2: Skin heating and irritation: Rare (<1%) – Wearing the NIRS probe for extended periods 
of time at once can theoretically lead to a warm feeling at the area where the probe is placed. 
However, this risk is minimal because the light emitted from this probe is not powerful enough 
to heat the skin. If you let the investigators know of any discomfort due to the probe, we will 
follow manufacturer guidelines to ensure the device is functioning correctly. 
Functional Near-infrared Spectroscopy (fNIRS): Risk of injury or discomfort is extremely 
low due to this device. Possible physical harms are, but not limited to: 
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Risk 1: Mild headache: Infrequent (1 – 10%) – High quality data from this device requires the 
placement of the probes in a snug headcap over the forehead, superficial to the prefrontal cortex. 
The slight pressure applied to the area may be slightly discomforting and unusual. 
Risk 2: Eye damage/irritation: Rare (<1%) – Please do not, at any point, stare into the light 
emitted from the fNIRS probe. 
Risk 3: Skin heating and irritation: Rare (<1%) – Wearing the fNIRS probe for extended periods 
of time at once can theoretically lead to a warm feeling at the area where the probe is placed. 
However, this risk is minimal because the light emitted from this probe is not powerful enough 
to heat the skin. If you let the investigators know of any discomfort due to the probe, we will 
follow manufacturer guidelines to ensure the device is functioning correctly. 
Transcranial Doppler (TCD): Data collection from this system requires the affixation of a 
headpiece to the participant. Risk of injury due to this device is extremely low. Possible harms 
may include, but are not limited to: 
Risk 1: Mild headache: Infrequent (1 – 10%) – High quality data from this device requires the 
placement of the probe over the middle cerebral artery (MCA) and posterior cerebral artery 
(PCA). The slight pressure applied to the area may be slightly discomforting and unusual for the 
participant. 
 




What if we learn about new findings or information during the study?  
You will be given any new information gained during the course of the study that might affect 
your willingness to continue your participation.  
The imaging we are using in this research study is not the same quality as imaging that you may 
have as part of your health care. The images will not be reviewed by a doctor who normally 
reads such images (such as a radiologist). As a result, you may not be informed of any 
unexpected findings. The results will not be placed in your medical record.  Occasionally the 
technologist or principal investigator may notice something abnormal on the imaging.  If this 
does occur, the images will be reviewed by a qualified doctor to determine if there is anything of 
clinical importance. If something is found to be important then you, and/or your primary care 
provider will be notified.  Any further follow up and costs associated with the incidental finding 
will be your responsibility. There may be benefits to learning such results (such as early 
detection and treatment of a medical condition), but there are risks as well (such as problems 
with getting insurance or a job or feeling worried about a finding for which no treatment is 
required or appropriate). 
  
Do you wish to be informed in case of clinical/relevant unexpected findings?  Please initial in the 
box below if you do not wish to be notified of clinical/relevant unexpected findings.  If you do 
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not initial in the box, you will be notified of any findings. 
  
 ______ I do not wish to be notified. 
Will I receive any other clinical results?  
There are no other clinically relevant results of this research that will be communicated with you. 
 
How will information about you be protected? 
The data generated from this study will be used for the purpose of scholarly publication and 
potentially for research presentation. Your personal data will not be identifiable.  
However, there is an inherent risk for a breach of confidentiality due to the sharing of personal 
information with the research team for research purposes.  
Breach of confidentiality will be minimized by limiting the number of research team members in 
the laboratory during any testing session. By needing key card access to the laboratory, we are 
limiting the number of individuals not on the research team who have access to the lab. Those 
who do have key card access are exercise physiology professors, PhD candidates, and Master’s 
candidates, and selected undergraduate students who are directly associated with the study and 
have performed all necessary trainings regarding sample handling, laboratory procedures, and 
confidentiality. All participants within the study are coded with an individual ID and no names 
will be identified in any document besides a master key document. This master key document 
will be kept in a locked drawer in the Cardiometabolic Laboratory within the Applied Physiology 
Laboratory. 
Participants will not be identified in any report or publication about this study.  We may use de-
identified data from this study in future research without additional consent. 
Although every effort will be made to keep research records private, there may be times when 
federal or state law requires the disclosure of such records, including personal information.  This 
is very unlikely, but if disclosure is ever required, UNC-Chapel Hill will take steps allowable by 
law to protect the privacy of personal information.  In some cases, your information in this 
research study could be reviewed by representatives of the University, research sponsors, or 
government agencies (for example, the FDA) for purposes such as quality control or safety. 
Recordings will be taken of verbal responses during the cognitive assessment to clarify scores for 
data analysis. Once data is successfully recorded into the data spreadsheet, the audio recording 
will be destroyed. Audio recording files will be kept less than 1 week in total. Audio recordings 
are not required but will help researchers to better record cognitive data. 
Recordings of the space in front of you will be made using Pupil Core. These videos may include 
parts of your body such as your hands, if held up close to the face. These videos are a 
requirement of the study. 
Check the line that best matches your choice: 
 




_____ Not OK to record me during the study 
 
What will happen if you are injured by this research? 
All research involves a chance that something bad might happen to you.  If you are hurt, become 
sick, or develop a reaction from something that was done as part of this study, the researcher will 
help you get medical care, but the University of North Carolina at Chapel Hill has not set aside 
funds to pay you for any such injuries, illnesses or reactions, or for the related medical care.  Any 
costs for medical expenses will be billed to you or your insurance company.  You may be 
responsible for any co-payments and your insurance may not cover the costs of study related 
injuries. 
If you think you have been injured from taking part in this study, call the Principal Investigator at 
the phone number provided on this consent form.  They will let you know what you should do.  
By signing this form, you do not give up your right to seek payment or other rights if you are 
harmed as a result of being in this study. 
What if you want to stop before your part in the study is complete? 
You can withdraw from this study at any time, without penalty.  The investigators also have the 
right to stop your participation at any time. This could be because you have had an unexpected 
reaction, or have failed to follow instructions, or because the entire study has been stopped. 
 
If you withdraw or are withdrawn from this study all data collected up until the point of 
withdrawal will be retained, however no additional information will be collected unless you 
provide additional written permission for further data collection at the time of your withdrawal.  
Will you receive anything for being in this study? 
You will not receive anything for taking part in this study. 
 
Will it cost you anything to be in this study? 
It will not cost you anything to be in this study.  
What if you are a UNC student? 
You may choose not to be in the study or to stop being in the study before it is over at any 
time.  This will not affect your class standing or grades at UNC-Chapel Hill.  You will not be 
offered or receive any special consideration if you take part in this research. 
What if you are a UNC employee? 
Taking part in this research is not a part of your University duties, and refusing will not affect 
your job.  You will not be offered or receive any special job-related consideration if you take part 
in this research. 
 
What if you have questions about this study? 
You have the right to ask, and have answered, any questions you may have about this research. If 
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you have questions about the study (including payments), complaints, concerns, or if a research-
related injury occurs, you should contact the researchers listed on the first page of this form. 
 
 
What if you have questions about your rights as a research participant? 
All research on human volunteers is reviewed by a committee that works to protect your rights 
and welfare.  If you have questions or concerns about your rights as a research subject, or if you 
would like to obtain information or offer input, you may contact the Institutional Review Board 






I have read the information provided above.  I have asked all the questions I have at this time.  I 
voluntarily agree to participate in this research study. 
 
______________________________________________________ 




Printed Name of Research Participant  
 
______________________________________________________ 




Printed Name of Research Team Member Obtaining Consent   
 
______________________________________________________ 
Signature of Witness if applicable, e.g., literacy issues, 
visually impaired, physically unable to sign, witness/interpreter for 
non-English speaking participants using the short form) 











APPENDIX B. SUBJECT PRE-ASSESSMENT INSTRUCTIONS 
Hello, 
This is a reminder email of your appointment at the Cardiometabolic Lab for “The Role of Blood 
Pooling In The Legs During Prolonged Sitting On Cardiovascular and Cerebrovascular 
Outcomes: A Mechanistic Study,” on _____ at _____.  The following pre-visit criteria must be 
met prior to your familiarization/experimental visit: 
 
For familiarization visits (Visit 1): 
- Abstain from alcohol 12 hours prior. 
- Abstain from caffeine 12 hours prior. 
- Wear comfortable clothes to the visit, such that your calves can be exposed easily. 
- If applicable, wear a sports bra for comfort and assess for ECG and skin temperature 
readings. 
The familiarization visit is expected to last approximately 45 minutes. 
 
For experimental visits (Visit 2 and 3) 
- Refrain from exercise for a period of 12 hours prior. 
- Consume nothing but water for a period of 8 hours prior.  
- Avoid consuming alcohol and caffeine for 12 hours prior. 
- Wear comfortable clothes to the visit, such that your calves can be exposed easily. 
- Do not wear lotion, sunscreen, or deodorant on the chest. 
- Avoid heavy make-up or mineral sunscreen on the forehead or temples. 
- Have at least one index finger free of nail polish or other varnish on the fingernail 
- Bring headphones to listen to videos during experiment (optional) 
Each experimental visit to is expected to last approximately 130 minutes. 
Please fill out the COVID-19 screening survey prior to each visit, either by scanning the QR 
code on the lab door upon arrival or filling out this link here: 
https://unc.az1.qualtrics.com/jfe/form/SV_9FxzSKmV2ezrU69 
The Cardiometabolic Lab is part of the Applied Physiology Lab, located in the basement of Fetzer 
Hall. From the front entrance, go straight past Gym A and down the stairs on the right. From the 
bottom of the stairs, move down the hall in the direction of the Student Recreation Center (SRC). 
Before moving up the ramp to the SRC, turn left and look for the sign for Applied Physiology Lab 
on the right. Make this right turn and you will find a small lobby to the lab on the left, where you 
will be greeted by a member of the Cardiometabolic Lab. 
If you have trouble finding the location, please call or text Katie at 919-360-7515 or Alex at 585-




APPENDIX C. SUPPLEMENTAL DATA 
 
INTRODUCTION TO SUPPLEMENT 
 
 Supplementary data for both trials are provided in this section for further interpretation. 
The LAY trial was primarily used as a quality control and was exploratory and therefore was not 
reported nor discussed independently from SIT in Chapters III and IV. The data for the SIT study 
that was presented in Figure 6 is supplemented in Table S1 to illustrate p-values, effect size, and 
beta constants for bfPWV. Additionally, Table S1 shows the bfPWV from the LAY study 
illustrated in Figure 8. Table S3 provides NIRS data for the SIT trial to elaborate on tissue 
saturation as well as changes in HHb, HbO2 and THb. Table S4 depicts NIRS changes by time 
and condition in the LAY study. Peripheral arterial stiffness and preload parameters are 
presented in Table S5. Additionally, LAY afterload and inotropy-related measurements can be 
found in Table S6. Lastly, the full demographic description of participants in the LAY and SIT 




Table S 1: Brachial-femoral pulse wave velocities reported as mean (standard deviation) before and after 





 m/s  m/s 
Cuff Pre 5.32 (0.71) Cuff Pre 5.91 (0.75)  
Post 5.57 (0.68) 
 
Post 6.25 (0.64) 
Non-Cuff Pre 5.88 (0.58) Non-Cuff Pre 6.36 (0.81) 
 Post 5.51 (0.94)  Post 6.94 (1.24) 
Condition Effect  Condition Effect   
 β 0.334  β 0.131 
 P 0.087  P 0.349 
 ES -0.370  ES 0.217 
Time Effect  Time Effect   
 β 0.027  β 0.175 
 P 0.858  P 0.196 
 ES -0.037  ES 0.302 
Interaction Effect 
 
Interaction Effect    
  β 0.665   β 0.284 
  P 0.044   P 0.280 
  ES -0.448   ES 0.251 
Abbreviations: β, beta; bfPWV, brachial-femoral pulse wave velocity (bfPWV); ES, effect size. 
P, p-value; Pre, experimental timepoint before prolonged sitting; Post, experimental timepoint 
after prolonged sitting; CUFF, occlusive cuff condition; NON CUFF, control condition 
 
Interpretation: A significant interaction effect for bfPWV indicates both prolonged lying and the 
inflated cuffs significantly increased this outcome of central arterial stiffness in the LAY trial. No 
significant change in central arterial stiffness was detected by condition, time nor interaction in 




Table S 2: Calf circumferences reported as mean (standard deviation) before and after 120 minutes of 





Condition Time cm Condition Time cm 
Cuff 1. Pre 34.73 (1.65) Cuff 1. Pre 35.00 (3.45) 
  2. post 35.45 (1.39)   2. post 36.34 (3.46) 
Non-Cuff 1. Pre 34.15 (1.65) Non-Cuff 1. Pre 35.00 (3.28) 
  2. post 34.33 (2.13)   2. post 35.08 (3.19) 
Condition Effect   Condition Effect   
  β 0.742   β 0.63 
  P 0.016   P < 0.001 
  ES 0.055   ES 2.27 
Time Effect   Time Effect   
  β 0.350   β 0.71 
  P 0.220   P <0.001 
  ES 0.261   ES 15.56 
Interaction Effect   Interaction Effect   
  β 0.333   β 1.26 
  P 0.551   P 0.001 
  ES 0.124   ES 2.27 
 
 
Abbreviations: β, beta; bfPWV; ES, effect size. P, p-value; Pre, experimental timepoint before 
prolonged sitting; Post, experimental timepoint after prolonged sitting; CUFF, occlusive cuff 
condition; NON CUFF, control condition 
 
Interpretation: A significant condition effect for calf circumference indicates that the presence of 
inflated cuffs significantly increased venous pooling in the LAY trial. No significant change in 
central arterial stiffness was detected by condition, time nor interaction. A significant interaction 
effect for calf circumference indicates both prolonged sitting and the inflated cuffs significantly 
increased venous pooling in the SIT condition. 
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Table S 3: NIRS measures reported as mean (standard deviation) before and after 120 minutes of sitting 
(n = 5) 
SIT condition Time TSI % HbO2 HHb THb 
CUFF Pre 61.3 (4.33) 54.1 (27.35) 35.7 (20.52) 89.8 (46.97) 
 Post 56.0 (10.35) 45.0 (27.10) 47.5 (55.56) 92.5 (82.59) 
 % Change -8.58 -16.7 32.9 2.97 
NON CUFF Pre 60.5 (7.35) 47.7 (21.63) 29.2 (8.55) 77.03 
 Post 56.7 (9.58) 66.4 (74.24) 27.2 (13.17) 93.6 (70.67) 
 % Change -6.26 39.06 -6.81 21.63 
Condition      
 β -0.250 2.00 18.3 20.26 
 P 0.905 0.872 0.023 0.230 
 ES -0.021 0.037 0.43 0.269 
Time      
 β 1.030 10.04 -1.90 9.66 
 P 0.697 0.594 0.962 0.816 
 ES 0.069 0.151 -0.04 0.105 
Interaction      
 β 1.468 -27.73 22.05 -14.0 
 P 0.943 0.376 0.491 0.446 
 ES -0.049 -0.212 0.21 -0.076 
 
 
Abbreviations: β, beta; TSI, tissue saturation index; HbO2, oxygenated hemoglobin; HHb, 
deoxygenated hemoglobin; ThB, total hemoglobin; ES, effect size. P, p-value; Pre, experimental 
timepoint before prolonged sitting; Post, experimental timepoint after prolonged sitting; CUFF, 
occlusive cuff condition; NON CUFF, control condition 
 
Interpretation: A significant time effect is present for tissue saturation index, which indicates 
that less oxygenated blood was present in the gastrocnemius after sitting. A significant condition 
demonstrates that more HHb was present in the calf with the inflated cuffs, suggesting that 





Table S 4: NIRS measures reported as mean (standard deviation) before and after 120 minutes of lying.  
(n = 6) 
LAY condition Time TSI % HbO2 HHb THb 
CUFF Pre 64.1 (6.18) 47.4 (15.96) 27.9 (9.32) 75.3 (23.87) 
 Post 53.6 (6.75) 46.3 (17.53) 40.0 (16.43) 86.3 (31.70) 
 % Change -16.4 -2.42 43.4 14.5 
NON CUFF Pre 99.7 (4.26) 50.7 (27.69) 25.5 (13.64) 76.1 (41.50) 
 Post 66.7 (0.42) 50.01 (25.11) 25.1 (15.45) 75.1 (40.05) 
 % Change 49.4 1.33 1.46 1.37 
Condition Effect     
 β 11.46 2.88 12.7 -10.60 
 P 0.001 0.615 0.010 0.354 
 ES 0.409 0.089 0.453 -0.178 
Time Effect     
 β 2.88 -0.241 1.29 4.78 
 P 0.175 0.837 0.976 0.813 
 ES 0.267 -0.006 0.038 0.08 
Interaction Effect     
 β 11.63 1.81 -12.2 -8.55 
 P 0.001 0.988 0.318 0.860 
 ES 0.722 0.024 -0.178 -0.060 
 
Abbreviations: β, beta; TSI, tissue saturation index; HbO2, oxygenated hemoglobin; HHb, 
deoxygenated hemoglobin; ThB, total hemoglobin; ES, effect size. P, p-value; Pre, experimental 
timepoint before prolonged sitting; Post, experimental timepoint after prolonged lying; CUFF, 
occlusive cuff condition; NON CUFF, control condition. 
 
Interpretation: A significant interaction effect present for tissue saturation index indicates that 
less oxygenated blood was present in the gastrocnemius both after lying and with cuff inflation. 
A significant condition effect demonstrates that more HHb was present in the calf with the 




Table S 5: Preload and cardiac output parameters in the LAY trial presented as mean (standard 
deviation) (n = 6) 
LAY condition CO SV SVV HR 
  Time L/min mL % Bpm 
Cuff Pre 5.64 (1.07) 77.3 (4.31) 18.0 (6.77) 73 (13) 
  Post 4.93(1.29) 77.8 (2.26) 17.1 (5.80) 63 (13) 
Non-Cuff Pre 4.85 (1.12) 73.4 (2.36) 23.8 (7.36) 65 (8) 
  Post 4.60 (1.05) 73.1 (3.11) 18.3 (4.94)   66 (12) 
Condition Effect     
  β 0.220 -1.45 -0.449 4.54 
  P 0.199 0.677 0.811 0.112 
  ES 0.271 -0.086 -0.050 0.341 
Time Effect     
  β -0.475 0.083 -3.20 -4.21 
  P 0.006 0.981 0.073 0.115 
  ES 0.634 0.005 0.386 0.34 
Interaction Effect     
  β 0.466 -0.833 -4.56 10.25 
  P 0.146 0.903 0.193 0.060 
  ES 0.309 -0.025 0.276 0.416 
. 
 
Abbreviations: β, beta; ES, effect size; CO, cardiac output; SV, stroke volume; SVV, stroke 
volume variation; HR, heart rate; P, p-value; Pre, experimental timepoint before prolonged 
sitting; Post, experimental timepoint after prolonged lying, CUFF, occlusive cuff condition; 
NON CUFF, control condition 
 
Interpretation: A significant time effect is present for cardiac output, which indicates that less 
oxygenated blood was present in the gastrocnemius after lying supine for 120 minutes. A 
significant interaction effect shows that HR decreased with both time and with the presence of 
cuff occlusion. SVV decreased with a time effect noted, suggesting that more fluid volume is less 




Table S 6: Afterload, inotropy and sympathetic nervous system parameters in the LAY trial, presented as 
mean (standard deviation) (n = 6). 
LAY 
condition 
Time GSR Skin temp SVR SMII MAP faPWV 
 µS °C dˑsˑcm-5 w/m2 mm Hg m/s 
Cuff Pre 4.55 (4.15) 34.55 (1.04) 1106 (215) 
18.00 
(6.77) 
78.8 (10.6) 6.68 (0.75) 
 Post 6.04 (5.39) 36.61 (0.87) 1470 (407) 
17.07 
(5.79) 
86.6 (13.9) 6.73 (2.10) 
Non-Cuff Pre 3.25 (3.60) 34.83 (0.51) 1349 (255) 
23.75 
(7.36) 
79.3 (8.00) 6.76 (1.12) 
 Post 4.41 (2.68) 35.24 (2.68) 1402 (400) 
18.27 
(4.94) 
80.1 (13.1) 7.61 (1.78) 
Condition Effect       
 β -0.149 -0.679 -171 -0.154 -3.31 0.371 
 P 0.089 0.062 0.099 0.156 0.376 0.332 
 ES 0.040 0.222 0.212 0.05 -0.186 0.203 
Time Effect       
 β 1.34 1.23 208 0.052 4.31 0.373 
 P 0.846 0.278 0.031 0.624 0.254 0.282 
 ES 0.371 0.410 0.301 0.23 0.243 0.206 
Interaction Effect       
 β -0.373 -1.65 311 -0.273 -6.89 0.795 
 P 0.804 0.198 0.091 0.206 0.358 0.299 
 ES 0.052 0.275 0.226 0.049 0.194 0.635 
 
Abbreviations: β, beta; ES, effect size; GSR, galvanic skin sensitivity; skin temp, skin 
temperature; SVR, systemic vascular resistance; SMII, Smith-Madigan Inotropy Index; MAP, 
mean arterial pressure; faPWV, femoral-arterial PWV; P, p-value; Pre, experimental timepoint 
before prolonged sitting; Post, experimental timepoint after prolonged lying, CUFF, occlusive 
cuff condition; NON CUFF, control condition 
 
Interpretation: A significant condition effect is present for GSR, which indicates that eccrine 
sweat gland activity increased with cuff inflation. SVR significantly increased with both lying 
and the presence of cuffs (interaction effect), demonstrating an increase in vascular resistance in 




Table S 7: Participant Characteristics for the SIT study (n = 5) and LAY study (n = 6). 












X 23.6 173.2 69.5 23.1 2.8 
40 
SD 5.3 10.8 11.2 3.2 0.3 












X 26.5 167.4 63.3 22.5 2.7 
66.7 
SD 7.6 9.0 9.2 2.3 0.3 
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